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ABSTRACT 
 
PARTICLE-BLOOD DYNAMICS: ADHESION OF VASCULAR-TARGETED 
PEGYLATED PARTICLES AND BLOOD CELLS IN FLOW 
 
by 
 
Peter Onyskiw Jr. 
 
 
Chair:  Lola Eniola-Adefeso, 
  
 Vascular targeting is a viable strategy for the therapeutic intervention of inflammatory 
diseases such as cardiovascular disease.  The multiple components of blood (red blood cell, 
leukocytes, platelets, and plasma) create a complex transport process for optimizing tissue 
specific targeting.  Attaching poly(ethylene glycol) (PEG) spacers to a drug carrier’s surface 
(PEGylation) is often proposed as a strategy for avoiding systemic clearance by minimizing 
plasma protein adsorption onto the drug carrier.  However, it is unclear as to whether PEGylation 
influences ligand-based tissue targeting in blood flow.  Additionally, both platelets and 
leukocytes localize and interact with the vessel wall during inflammation.  Little is known 
whether the presence of inflammation targeting drug carriers in blood or at the vessel wall 
influences the homeostatic interaction of leukocytes and platelets with the same targeted tissue.  
Here, I investigate the dynamics between the non-red cell components of blood and vascular 
xvi 
targeted carriers; specifically, how PEGylation influences carrier adhesion in blood and whether 
inflammation targeting drug carriers affect leukocyte and platelet adhesion to the same targeted 
tissue.  The addition of a 5.5 kDa or 10 kDa PEG spacer to a model drug carrier improved 
targeting to a model vessel wall in laminar human blood flow, but only for an unfavorable 
targeting system (aICAM-1/ICAM-1).  While PEGylation was unable to neutralize a negative 
plasma effect on the adhesion of an actual drug delivery system (poly(lactic-co-glycolic) acid 
spheres) in human blood, a PEG surface density of 35,000 PEG chains/µm
2 
maintained the 
adhesiveness of a model drug carrier in pig blood.   Also, high blood concentrations of 500 nm-5 
µm targeted spheres (2.5x10
6
 particles/mL and 1x10
7
 particles/mL) were found to reduce the 
adhesion of leukocytes to the same targeted tissue under high shear conditions, with nearly a 
100% reduction in leukocyte adhesion with 5 µm and 3 µm targeted spheres at 1x10
7
 
particles/mL in blood.  This work contributes to the design and application of targeted drug 
carriers by recommending a 5.5 kDa or 10 kDa PEG spacer for targeting high shear areas 
associated with cardiovascular disease and identifying a new application for inflammation 
targeting particles through reducing leukocyte accumulation to inflammatory tissue.  
 
  
1 
CHAPTER 1  
 
INTRODUCTION 
 
 
1.1. Background  
The vasculature of the human body is the network of vessels through which blood is 
pumped by the heart in order to sustain organ and muscle function.  Blood is responsible for 
transporting vital nutrients to and from organs, immune cells to sites of infection, and is directly 
involved in repairing damaged vessels after vascular injury.  During healthy function, blood is 
circulated throughout the body with limited interactions with the vasculature tissue itself.  
However under distress, the vascular wall uses inflammation to signal immune cells and other 
blood cells to the stimulated site in order to restore the tissue to homeostatic function.  Even 
though the inflammatory signaling process is vital for the body’s immune system and 
sustainability, unregulated or chronic inflammation can significantly enhance the pathogenesis of 
a several serious injuries.  For example, circulating cancer cells localize and interact with 
inflamed vessels before transmigrating into local tissue and initializing tumor proliferation.[1]  
The continuous inflammatory recruitment of T-cells, macrophages, and other leukocytes into the 
pulmonary tissue is responsible for airway obstruction and hyper-responsiveness associated with 
chronic obstructive pulmonary disorder and asthma.[2]  Of the many other inflammatory 
diseases, cardiovascular disease (CVD) is one of the most common diseases associated with 
vascular inflammation.    
2 
Despite the steady decline in cardiovascular deaths since the 1980s, cardiovascular 
disease remains the leading cause of death in the United States and the Western World.[3, 4] 
Atherosclerosis is a chronic inflammatory disease in which the continuous recruitment of 
leukocytes (white blood cells) to atheroprone areas results in plaque formation between the 
endothelium, the monolayer of cells lining the lumen of blood vessels, and the underlying 
smooth muscle tissue (Fig. 1.1).[5, 6]  Plaque development is a major concern for CVD due to 
the potential for rupture and inducing life-threatening cardiac events such as a stroke or heart 
attack.  Current diagnostic techniques for atherosclerosis include contrast imaging or measuring 
cholesterol levels via blood tests.[7, 8]  However, these methods do not provide detailed analysis 
of atherosclerotic tissue or identify early stages of plaque formation and potential areas of lesion 
development such as chronically inflamed tissue.  
 
 
 
Figure 1.1.  Schematic of (A) leukocyte recruitment, (B) plaque    
      development, and (C) plaque rupture as related to atherosclerosis.[6] 
 
3 
Oral administration of therapeutics such as statins is often prescribed as a non-invasive 
therapy for treating and preventing plaque formation.[9]  Though there are many benefits to 
statin therapy, including stabilizing atherosclerotic plaque to minimize rupture and decreasing 
overall inflammatory response of the endothelium, there are several serious side-effects 
associated with the systemic circulation of statins.[10]  For example, statins decrease platelet 
activation and endothelial inflammation which is therapeutically beneficial for atherosclerotic 
tissue but can negatively impact clotting time and the inflammatory recruitment of immune cells 
during vessel injury and local infection.[11-13]  However, many of these systemic side effects 
can be minimized by reducing exposure of the therapeutic to healthy tissue.  Targeted drug 
delivery is a tissue-specific therapeutic strategy aimed towards minimizing harmful side-effects 
through delivering therapeutics directly to diseased tissue.  Vascular targeting utilizes blood flow 
to deliver targeted drug carriers directly to diseased vasculature and is a strong candidate for 
treating inflammation associated with CVD due to blood directly contacting the diseased tissue, 
i.e. the inflamed endothelium of blood vessels.   
 
1.1.1. Utilizing Inflammation for Tissue Specific Targeting 
 
 Inflammation is a biochemical signaling response of the endothelium to external 
stimulants such as a local infection, vessel injury, or cholesterol accumulation in the vessel wall.  
External stimulation induces the production of cytokines such as interleukin-1β (IL-1β) and 
tumor necrosis factor-α (TNFα) which initiates changes in molecular pathways and alters the 
receptor expression of the endothelium.[14-16]  The primary role of inflammation is to recruit 
leukocytes to the stimulated tissue in order to return the tissue to homeostatic function.  After 
exposure to cytokines, the endothelium upregulates cell adhesion molecules (CAMs) including 
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P- and E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion 
molecule-1 (VCAM-1) which initiate the leukocyte adhesion cascade (Fig. 1.2).[17, 18, 19]  
First, leukocytes are initially captured from blood and roll along the activated endothelium 
through P- and E-selectin interacting with leukocyte expressed ligands including sialyl lewis
x
 
(sLe
x
), sialyl lewis
a
 (sLe
a
), and P-selectin glycoprotein-1 (PSGL-1).[20, 21]  Leukocyte rolling is 
the continuous formation and breaking of bonds with selectins on the endothelium which results 
in leukocytes translocating across the endothelium in the direction of blood flow.  The decreased 
velocities of rolling leukocytes, relative the velocity of freely circulating leukocytes in blood, 
allows for firm adhesion to be established via lymphocyte function-antigen-1 (LFA-1) and α4β1 
integrin (VLA-4) interacting with ICAM-1 or VCAM-1, respectfully.[22]  After firm adhesion is 
established, leukocytes localize to cell-cell junctions, transmigrate between adjacent cells into 
tissue, and begin to work towards returning the stimulated tissue to normal function.  CAMs 
make viable targets for inflammation specific drug delivery associated with CVD by marked 
characteristics such as low basal expression of CAMs by healthy tissue, up-regulation during 
acute and chronic inflammation, and prevalence near atherosclerotic lesions.[23, 24]  
 
 
Figure 1.2.  Schematic of leukocyte adhesion cascade.[17] 
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1.1.2. Design of Vascular-Targeted Carriers 
 Several formulations can be implemented as the drug delivery vehicle used for vascular 
targeted.  Liposomes are attractive for vascular targeting due to their low toxicity and are easy to 
fabricate.  Liposomes are composed of an inner aqueous phase encapsulated by a lipid bilayer.  
Hydrophilic drugs can be easily loaded into the aqueous phase during fabrication; however, 
hydrophobic drugs are restricted to the lipid membrane.[25]  The fluidity of the lipid membrane 
significantly impacts hydrophobic drug retention, particularly under high shear.[26]  The lipid 
membrane can be stabilized with the addition of poly(ethylene glycol) (PEG); however, the steric 
hindrance provided by PEG significantly decreases cellular internalization and reduces the 
potential for intracellular drug delivery with liposomes.[27, 28]  Porous materials such as silicon 
dioxide (silica) and titanium dioxide have also been explored for vascular targeting; however, 
therapeutic loading through physio-adsorption makes it difficult to control drug release.[29]  
Gold and iron oxide nanoparticles have also been implemented in MRI and x-ray imaging of 
atherosclerotic plaque, although drug loading remains an issue due to the lack of control of the 
pore size during particle fabrication.[30]   
 Polymeric spheres are one of the most popular formulations explored for vascular 
targeting.  Biodegradable polymers allows for tailored drug release through control of the 
polymer’s molecular weight, crystallinity, and hydrophobicity.[31]  Targeting ligands can be 
attached to functional groups on the particle’s surface provided by the polymer’s end- or side 
chains.  Polymeric particles can also be fabricated in a variety of sizes and shapes using scalable 
oil-in-water emulsion techniques, making polymeric vascular-targeted carriers (VTCs) a strong 
candidate for treating CVD and optimizing tissue targeting in blood flow.[33-35] 
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In order for VTCs to effectively target the inflammation, they must first marginate to the 
vessel wall in flow before establishing firm adhesion through targeted ligands interacting with 
inflammatory receptors (i.e. CAMs).  Margination is the localization to the vessel wall from bulk 
blood flow.  Firm adhesion to the vessel wall is established by decorating the VTC’s surface with 
ligands which interact with CAMs.  E-selectin, ICAM-1, and VCAM-1 have all been proposed 
as inflammatory target molecules; however, their difference in expression during inflammation 
and reaction kinetics must be considered when optimizing VTCs.  For example, E-selectin is 
often targeted using sialylated tetrasacchrides such as sLe
x
 or sLe
a
 found naturally on leukocytes 
(sLe
a
/sLe
x
 also interact with P-selectin on endothelial cells and platelets, and L-selectin found on 
leukocytes).[21]  Even though E-selectin plays a significant role in rolling adhesion, firm 
adhesion can be established by decorating the VTC’s surface with multivalent sLea or by 
decorating the VTC’s surface with ligand densities greater than ~800 sLea sites/µm2.[36, 37]  
Targeting ICAM-1 or VCAM-1 typically requires higher ligand densities >2,000 ligands/µm
2
 for 
adhesion under high shear conditions (>200 s
-1
 wall shear rate) due to slower reaction kinetics 
relative to that of selectins with sLe
a
/
x
.[36, 38]  P- and E-selectin are also upregulated during 
acute inflammation and not during chronic inflammation associated with CVD.  For this reason, 
ICAM-1 and VCAM-1 are often targeted, using peptides or antibodies, in conjugation with E-
selectin, due to their upregulation during chronic inflammation and around atherosclerotic 
lesions.[23, 38-41]   
Physical and material characteristics of VTCs including size, shape, and VTC density 
have all been shown to significantly impact margination and adhesion in hydrodynamic and 
blood flow.[42-45]  For example, in blood, silica particles were shown to marginate more 
effectively to the vessel wall than neutrally buoyant polystyrene spheres which were 
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approximately 2.5-fold lower in particle density (Thompson. In submission. 2015).  Ellipsoidal 
(rod-shaped) and disk-shaped particles have been shown to marginate more efficiently than 
spherical particles in hydrodynamic flow, as ellipsoids naturally drift away from the center of 
flow.[43]  Ellipsoidal particles also align in the direction of flow which helps reduce the potential 
for vessel occlusion and accumulation in organs such as the lungs and liver.[46, 47]  Changing 
particle shape can also influence adhesive dynamics in flow as ellipsoidal particles were shown 
to have a greater propensity for adhesion due to ellipsoids having less rotational momentum, 
relative to spheres of the same volume, when interacting with targeted receptors at the vessel 
wall.[42, 44]  In summary, VTC geometry and targeting system are important design parameters 
probed for optimizing margination and adhesion in flow; however, vascular targeting is also 
influenced by hemodynamics and blood rheology.  
 
1.1.3.  Influence of Blood Rheology on VTC Margination and Adhesion  
1.1.3.a.  Red Blood Cell Effect on VTC Targeting 
 When optimizing VTC targeting in flow, it is important to remember that blood is the 
end-all working fluid and the rheological properties of blood play a significant role in VTC 
margination and adhesion.  Blood is a suspension of red blood cells (RBCs), leukocytes (white 
blood cells), and platelets in plasma – a concentrated aqueous solution of proteins and other 
biochemeicals.  RBCs constitute 40–45% of the total volume of blood (hematocrit - the volume 
percent of RBCs in blood) and play a significant role in VTC margination and adhesion.[48]  
RBCs’ deformability and disk shape induce an inertial lift during flow such that RBCs align in 
the center of flow and generate a RBC-free layer, more commonly the cell-free layer (CFL), 
several microns thick adjacent to the vessel wall (Fig. 1.3).[49-51]  Differences in rigidity, vessel 
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wall induced lift forces, and heterogeneous collisions with RBCs force more rigid blood cells 
(leukocytes and platelets) and VTCs to marginate towards to the CFL along the endothelium.[50]  
RBC induced margination of leukocytes has significant implications in atherosclerotic plaque 
development such that plaque develops in areas of disturbed flow, such as branching points or 
recirculation eddies, where marginating leukocytes can accumulate near low shear areas or 
stagnation points.[52, 53]  RBCs also promote firm adhesion to an endothelium by providing a 
normal force to the marginating VTCs and blood cells which aides in counteracting drag forces 
experienced at the vessel wall during flow.[36]   
 
 
 
 
 
 
Figure 1.3.  Schematic of the RBC-core and cell-free layer and 
influence on particle margination.[51] 
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The combined effect of enhanced margination and improved adhesion by the presence of 
red cells has a drastic effect on the influence of VTC size, geometry, and targeting ability.  For 
example in buffer-only hydrodynamic flow, targeted 5 µm polystyrene microspheres effectively 
adhere to an activated human umbilical vein endothelial (HUVEC) monolayer at adhesion 
densities greater than 2 µm targeted spheres.[36]  However with the presence of RBCs, the 
margination of 2 µm spheres is significantly enhanced such that the adhesion of 2 µm spheres is 
greater than 5 µm targeted spheres with the same ligand density.[36]  In fact, 2–3 µm spheres are 
suggested to be the optimal size of VTC margination and adhesion under RBC flow conditions in 
laminar and oscillating flow conditions.[54]  RBCs also promoted the adhesion of 5 µm sLe
a
-
targeted spheres at high wall shear rates (WSR >500 s
-1
) where adhesion was minimal in buffer 
only systems.[36]  The formation of an RBC core in bulk blood flow also significantly impacts 
the margination and adhesion of spheres < 1 µm such that submicron VTCs do not effectively 
navigate the RBC core ( RBC ~ 6  µm in diameter) and marginate to the vessel wall (Fig. 1.3), 
resulting in lower adhesion levels relative to microspheres (2-5 µm) in vivo and in vitro.[36, 37, 
51].  This provides a serious challenge for implementing nanospheres for targeted intracellular 
delivery.  Hence, changing VTC shape has been proposed as a means for improving nanosphere 
adhesion as ellipsoidal particles showed higher levels of margination in buffer-only systems.[42-
45]  While ellipsoidal VTCs if different aspect ratios (ratio of major length to minor length) 
showed enhanced margination in buffer-only systems, only ellipsoids with aspect ratios >9  
showed enhanced adhesion with the presence of RBCs in vitro.[42]  Hence, it is clearly evident 
that optimizing VTC adhesion in buffer-only systems does not translate to VTC targeting in 
blood flow due to the significant effect on margination and adhesion from the development of 
the RBC core during blood flow. 
10 
 
1.1.3.b.  Plasma Impact on VTC Targeting 
 
 Plasma has both physical and biochemical influences on VTC targeting.  Plasma provides 
a physical barrier between the vessel wall and the RBC-core which VTCs must cross before 
interacting with their targeted molecules.  Once bound to the endothelium, VTCs experience 
viscous drag forces due to the continuous flow of plasma.  If the adhesive dynamics are not 
sufficient to withstand the drag forces from plasma, VTCs will not adhere to or will be removed 
from the target site.  Thus, the shear stresses provided by plasma play a critical role in 
identifying molecular targeting systems and optimizing the ligand density required for firm 
adhesion to the vessel wall.   
 When exposed to blood, plasma proteins rapidly adsorb onto a particle’s surface.  The 
adsorption of opsins (G-protein coupled receptors) onto a particle’s surface is a key identification 
marker for the phagocytic cells before they initiate clearance from blood.[57, 58]  Protein 
adsorption also influences biodistribution such that opsonized particles are readily trafficked to 
the liver and spleen.  Plasma protein adsorption is dependent on both physical (size, shape) and 
chemical (surface charge, functionalization) characteristics of the VTC.[59]  For example, 
NIPAM-BAM (N-isopropylacrylamide N-tert-butylacrylamide) polymeric nanospheres ranging 
from 70 – 700 nm in diameter were shown to have similar protein adsorption profiles (types of 
proteins adsorbed onto the particle’s surface) but differ in the amount of proteins adsorbed onto 
the surface.[58]  A similar size effect on plasma adsorption has been identified with materials 
used for optimizing inflammation targeting VTCs including silica and polystyrene spheres.[60]  
While geometry and surface curvature influence the amount of protein adsorbed onto a particle, 
VTC chemical characteristics such as hydrophobicity and surface charge affects the types of 
proteins adsorbed onto a particle’s surface.  For example, proteins with isoelectric points less 
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than 5.5 (pH where protein charge is neutralized), such as albumin, were shown to have a greater 
affinity for adsorbing onto positively charged polymeric spheres, whereas negatively charged 
spheres showed larger amounts of adsorbed proteins with isoelectric points greater than 5.5.[58]  
A difference in affinity for protein adsorption was also shown to have a direct influence on VTC 
adhesion.  The presence of particular human plasma proteins adsorbed onto poly(lactic-co-
glycolic acid) (PLGA), but not polystyrene, targeted microspheres significantly reduced the 
adhesion of sLe
a
-targeted PLGA spheres in human plasma, relative to their adhesion in plasma-
free systems.[33]  On the other hand, the adhesion of polystyrene spheres to an activated 
endothelium in blood was not shown to be dependent on exposure to plasma proteins.[33]  
Hence, optimizing VTC targeting using model drug carriers (i.e. polystyrene spheres) in plasma 
systems does not guarantee optimal targeting of VTCs made from other materials, such as 
PLGA, due to the negative effect on adhesion from adsorbed plasma proteins being dependent on 
VTC material.  However, it may be possible to neutralize this material dependency of decreased 
VTC adhesion due to plasma adsorption using PEGylation.  
PEGylation is a strategy often implemented for minimizing plasma protein adsorption 
and consists of attaching poly(ethylene glycol) (PEG) chains onto a particle’s surface through 
covalent chemistry, physio-adsorption, or during VTC fabrication itself (such as PEG induced 
stabilization during liposome formulation).  The hydrophilic nature of PEG generates a water-
shell around the polymer chain which sterically prevents proteins from adsorbing onto a 
particle’s surface.[61]  PEGylation for reducing plasma adsorption has been widely studied and 
shown to increase in vivo circulation time and biodistribution, relative to non-PEGylated 
spheres.[56, 62]  Improving circulatory retention and biodistribution in turn increases the 
probability of tissue targeting, particularly for passive targeting strategies (targeting due to the 
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physical relationship between VTC and vessel geometry) such as lung entrapment.  However, it 
is unclear what effect PEGylation has on ligand-based targeting, which would require the 
targeting ligand to be placed on the end of a PEG chain.  Previous work with bimodal PEGylated 
systems (particles PEGylated with different sized PEG spacers) has shown that adhesive 
dynamics are reduced when the ligand were attached to a PEG spacer that was shorter than 
adjacent non-ligated PEG chains, due to the steric hindrance provided by the larger PEG 
chains.[63, 64]  PEG chain flexibility was also shown to improve receptor-ligand dynamics 
resulting in improved adhesive flux under low shear (RBC-free) conditions.[65]  However, it 
remains unclear if the influence of PEG on receptor-ligand dynamics correlates with differences 
VTC adhesion, relative to non-PEGylated VTCs, in blood under physiological flow conditions.  
Also, to my knowledge, PEGylation has not been directly examined as a strategy for restoring 
the adhesion of plasma-sensitive VTCs (VTCs which exhibited reductions in adhesion in plasma 
systems, relative to plasma-free systems, due to the adsorption of specific plasma proteins) 
despite the fact that PEGylation has been widely implemented for reducing plasma protein 
adsorption. 
 
1.1.3.c.  Influence of VTC-Leukocyte Dynamics on VTC Function 
 
 Even though RBCs constitute the largest subclass of blood cells, particle dynamics with 
leukocytes play a significant role in blood compatibility and overall VTC efficacy.  The primary 
function of neutrophils, monocytes, and macrophages (subclasses of leukocytes) is to localize to 
the inflammatory site and remove the foreign entities which induced the inflammatory response 
(i.e. pathogens during infection).  Hence, VTCs present at inflammatory tissue will encounter 
recruited leukocytes and VTC recognition by phagocytic cells will result in the removal of VTCs 
from the targeted tissue.  As a result, particle-leukocyte dynamics have been primarily 
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investigated with the intention of minimizing leukocyte phagocytosis and recognition.  Particle 
geometry (size and shape), surface charge, and VTC chemistry have all be explored for 
minimizing phagocytosis and macrophage clearance from the targeted tissue.[47, 66, 67]  
However, the influence of leukocytes on VTC design and function is not limited to phagocytosis 
and systemic clearance.  The propensity of leukocytes to marginate to the RBC-free layer and 
interact with CAMs upregulated during inflammation has significant implications on VTC 
targeting such that the presence of leukocytes were shown to significantly reduce the adhesion 
density of E-selectin targeting 2 and 5 µm spheres.[55]  This suggests that VTC targeting is 
sensitive to leukocyte concentration in blood which may be altered due to disease or 
pharmacological side effects, an assessment that would not be identified if VTC adhesion was 
only examined in leukocyte-free systems.  
 It is also important to identify whether the presence of VTCs has any impact on 
leukocyte function; specifically, do inflammation targeting VTCs influence leukocyte 
recruitment and adhesion to the same inflammatory tissue?  VTCs are targeted to inflammatory 
tissue through targeting moieties that interact with CAMs (such as E-selectin, ICAM-1, and 
VCAM-1) which are directly involved in the leukocyte recruitment cascade.  Hence in blood 
flow, the margination of both VTCs and leukocytes to the vessel wall and propensity to interact 
with upregulated CAMs may create competition for the targeted receptors which may have 
significant implications on leukocyte recruitment to the targeted vessel wall.  While an increase 
in leukocyte recruitment may potentially accelerate VTC removal from the targeted tissue 
through leukocyte phagocytosis, reducing leukocyte adhesion may prolong VTC retention and 
possibly provide additional therapeutic benefits to diseases such as atherosclerosis and 
reperfusion injury, where leukocyte recruitment contributes to disease pathogenesis.  To my 
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knowledge, the influence of VTCs in blood on leukocyte recruitment to targeted inflammatory 
tissue has not been thoroughly investigated and whether an effect, if any, from particle-leukocyte 
dynamics on leukocyte adhesion is sensitive to VTC design (i.e. targeting system, VTC size, and 
shape).  
 
1.1.3.d.  VTCs and Platelet Function 
 
 The primary role of platelets is to reduce blood loss during vessel injury.  Because of 
their geometry and difference in elasticity relative to RBCs, platelets readily marginate and 
circulate the vasculature on the peripheries of the blood vessels.  Upon activation or exposure to 
extracellular matrix proteins (i.e. collagen, fibrinogen), platelets rapidly adhere and aggregate at 
the injury site to minimize blood loss during vessel injury.  Unactivated platelets do not regularly 
interact with the vessel wall due to the endothelium releasing mediators such as nitric oxide and 
prostacyclin, which keep circulating platelets in a quiescent state; however, there are cases in 
which disease pathogenesis is enhanced due to the adhesion of activated platelets to inflamed 
endothelium.[68]  For example, circulating tumor cells (CTCs) activate and aggregate with 
platelets such that activated platelets coat the CTC’s surface and act as a protective shield from 
systemic clearance.  The activated platelets then facilitate CTC adhesion to inflammatory sites 
followed by CTC migration into tissue.[69]  In venous thrombosis, activated platelets initiate 
blood coagulation on the vessel wall after which the thrombus (aggregated platelets cross-linked 
with a fibrin network) may rupture due to shear stress and initiate a cardiac event such as a stroke 
or myocardial infarction (heart attack).[70]  For VTCs to be fully biocompatible with blood, it is 
crucial that they do hinder platelet function where necessary (i.e. vascular injury) or induce 
platelet activation and aggregation at the targeted tissue.   
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 Conversely, there are situations in which inducing platelet adhesion and aggregation are 
beneficial such as aiding in the clotting time of patients with thrombocytopenia (low platelet 
concentration, <1x10
8
 platelets/mL) or decreased platelet function.[71]  Synthetic platelets are 
VTCs designed to mimic platelet function by adhering to exposed extracellular matrix proteins 
(ECM) and aggregating with activated platelets to initiate a platelet plug at the site of vessel 
injury.  While collagen is often targeted by synthetic platelets to establish adhesion to injured 
blood vessels, platelet adhesion and aggregation to the ECM under high shear stress (>800 s
-1
) 
involves the interaction between platelets and vWF which is released by locally inflamed 
endothelium or deposited from soluble forms in plasma.[72]  For this reason, platelet mimicking 
VTCs are often decorated with multiple ligands in order to enable ECM targeting in a range of 
blood flow rates.[73]  Peptides that bind to collagen or vWF have been explored as targeting 
motifs due to their small size, relative to recombinant proteins, limiting steric hindrance when 
implemented on nanoparticles and scalability for commercialization.[74]  Adhesion to collagen 
can be established through collagen binding peptides (CBP), which are small sequences of -
[Glycine-Proline-Hydroxyproline]7-10- that self-assemble with similar sequences exposed on 
damaged collagen fibers.[74-76]  Von Willebrand binding peptides (VBP) have been identified 
from coagulation factor VIII which is coupled with soluble vWF prior to the initiation of the 
coagulation cascade.[76]  Linear or cyclic Arginine-Glycine-Aspartic Acid (cRGD) is often 
added to the target system to mediate VTC-platelet co-localization to the ECM and initiate 
aggregation and platelet plug formation at an injury site.[77]  Nano-sized liposomes (150-200 
nm) with a tri-peptide targeting system composed of collagen and vWF binding peptides along 
with, VBP, and cRGD have been shown to effectively mimic platelet function; however, there 
has been little work examining whether microspheres (2-3 µm in diameter) are equally or more 
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effective in promoting platelet function due their ability to readily marginate to the vessel wall in 
blood flow relative to nanospheres.[73-75] 
  
1.2. Summary of Work 
 The complexity of blood provides a unique challenge when optimizing VTC design for 
targeting inflammation in blood flow.  While RBCs are the largest volume percent of blood cells 
and 40–45% (by volume) of blood, VTC optimization in leukocyte- or plasma-free systems do 
not provide the complete dynamic environment of blood for evaluating VTC efficacy.  It is also 
crucial to understand what influences VTCs have on blood cell function such that VTCs 
designed for treatment do not accelerate or initiate abnormal blood cell function.  Investigating 
whether inflammation targeting particles alter the recruitment of platelets and leukocytes to the 
same targeted tissue may also have therapeutic benefits for diseases associated with platelet or 
leukocyte accumulation.  The aim of this work is to investigate the relationship between VTC 
adhesion and the non-RBC components of blood in order to gain insight into how particle-blood 
dynamics influence VTC design and application.  First, the influence of VTC-plasma dynamics 
on particle adhesion is explored with the PEGylation.  Specifically, I investigate whether the 
strategy of attaching PEG spacers onto a particle’s surface for minimizing plasma adsorption 
influences ligand-based targeting in blood flow and whether there is a dependency on the PEG 
corona properties (PEG molecular weight, conformation) on adhesion.  Once the influence of 
PEGylation on VTC adhesion in blood is understood via model polystyrene VTCs, I examine if 
PEGylation can be implemented to improve the adhesion of an actual drug delivery system in 
blood whose adhesion is sensitive to plasma protein adsorption.   I also examine VTC-leukocyte 
and VTC-platelet dynamics and whether presence of VTCs in blood significantly impacts blood 
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cell recruitment to an inflamed endothelium to determine if particle-blood cell dynamics 
influences blood cell function during inflammation.  The results from this dissertation have 
significant impact on improving VTC adhesion in blood flow through PEGylation and raises 
awareness to a new relationship between circulating VTCs and blood cell function. 
 
1.3. Thesis Outline 
 
Chapter 1 provides background and scope of the dissertation. 
Chapter 2 contains the materials, preparations, and protocols for the experiments 
conducted for Chapters 3 – 6. 
Chapter 3 explores the influence of PEGylation on ligand based adhesion of 
inflammation targeting VTCs in blood.  Briefly, 2 µm and 500 nm polystyrene spheres were 
conjugated with a 2.3 kDa, 5.5 kDa, or 10 kDa PEG spacer at a range of PEG grafting densities.  
The particle adhesion in laminar blood flow to an activated human umbilical endothelial vein 
(HUVEC) monolayer was examined over a range of physiological wall shear rates (200 s
-1–1,000 
s
-1
) using a parallel plate flow chamber.  The results of this work provide insight into the 
relationship between VTC adhesion in blood and PEGylation, and identify situations where 
vascular targeting benefits from PEGylation.  
Chapter 4 expands on the relationship between PEGylation and VTC adhesion in blood 
as PEGylation was implored to determine if the addition of PEG can improve the adhesion of a 
model and actual drug delivery system, which were previously shown to be sensitive to plasma 
protein adsorption.   
Chapter 5 investigates the influence of inflammation targeting VTCs on leukocyte 
adhesion in blood flow.  VTC parameters such as particle size, shape, blood concentration, and 
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targeting system along with hemodynamics were altered to explore (1) whether VTCs in blood 
affect the inflammatory recruitment of leukocytes to and activated endothelium, and (2) the 
dependency of leukocyte adhesion to VTC design and hemodynamics.  This work demonstrates 
that particle-leukocyte dynamics have significant implications on the inflammatory recruitment 
of leukocytes in blood flow. 
Chapter 6 explores the impact of particle-platelet dynamics on platelet adhesion to an 
activated endothelium and extracellular matrix proteins (collagen and vWF).  Specifically, the 
adhesion of unactivated and activated platelets was examined with presence of 2 µm sLe
a
-
targeted spheres and spheres containing collagen and vWF binding peptides.  The aims of this 
work was to (1) determine if the presence of sLe
a
-targeted spheres alters the homeostatic 
interaction between an activated endothelium and platelets and (2) whether 2 µm platelet 
mimicking VTCs can enhance platelet adhesion to collagen or vWF in order to improve clotting 
time for patients with low platelet concentration in blood.  The results of this chapter offer 
insight into the blood-compatibility of VTCs and their influence on platelet function. 
Chapter 7 provides significant conclusions from the experimental work and potential 
future directions.   
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CHAPTER 2  
 
MATERIALS AND METHODS 
 
 
This chapter describes all protocols, in detail, particle and blood preparation, and blood 
along with adhesion assays.  In general, particles were ligated using avidin-biotin coupling and 
ligand densities determined using flow cytometry.  Flow assays were conducted using a parallel 
plate flow chamber and human blood (Chapters 3-6) or pig blood (Chapter 4) at 37°C.  Particle, 
platelet, and leukocyte adhesion to an activated human umbilical vein endothelial cell monolayer 
(HUVEC) was assessed via brightfield or fluorescent microscope equipped with a digital camera 
and the adhesion densities normalized to imaged surface area.     
  
2.1. Materials   
Carboxylated polystyrene spheres (5.01 µm, 5.07 µm, and 2.07 µm), streptavidin spheres 
(200 nm), Quantum PE and FITC MESF calibration beads were purchased from Bangs 
Laboratories (Fishers, IN); carboxylated polystyrene spheres (2.1 µm, 3.1 µm, 0.5217 µm) were 
purchased from Polysciences, Inc. (Warrington, PA); NeutrAvidin and Avidin-fluorescein was 
purchased from Pierce Protein Biology Products-Thermo Fisher Scientific, Inc. (Rockford, IL); 
Biotinylated-PEG-Amine (2.3 kDa, 5.5 kDa, and 10 kDa) was purchased from Laysan Bio, Inc. 
(Arab, AL); multivalent biotinylated Sialyl Lewis
a
 and parallel plate flow chamber were 
purchased from GlycoTech (Gaithersburg, MD); biotinylated human ICAM-1 antibody (aICAM) 
clone BBIG-11, thrombin were purchased from R&D Systems (Pittsburgh, PA);  biotinylated-
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PEG(3.4 kDa)-collagen binding peptide, biotinylated-PEG(3.4 kDa)-collagen binding peptide-
fluorescein, biotinylated-PEG(3.4 kDa)-vWF binding peptide, and cyclic RGD peptide were 
synthesized by Dr. Anirban Sen Gupta’s research group (Case Western Reserve University, 
Cleveland, OH); biotin-fluorescein was purchased from Molecular Probes (Carlsbad, CA); PE-
labeled anti-human cutaneous lymphocyte antigen, PE-labeled anti-biotin were purchased from 
Miltenyi Biotec (San Diego, CA); goat anti-mouse IgG-fluorescein was purchased from Jackson 
Immuno Research Labs (West Grove, PA); PE-labeled rat IgM isotype and endothelial cell 
growth supplement were purchased from BD Biosciences (San Jose, CA); M199, fungizone, 
penicillin/streptomycin, HEPES buffer were purchased from, calcein AM green were purchased 
from LifeTechnologies (Grand Island, NY); Hyclone bovine calf serum, Hyclone phosphate 
buffered saline (minus calcium and magnesium ions), and glutamine, glutaraldehyde, acetic acid, 
Gibco phosphate buffered saline (with magnesium and calcium ions) were purchased from 
Thermo-Fisher Scientific (Rockford, IL); fetal bovine calf serum was purchased from Cell 
Generation (Fort Collins, CO); collagen type I form rat tail was purchased from Olaf 
Pharmaceuticals (Worcester, MA); vWF was purchased from Haematologic Technologies Inc. 
(Essex Junction, VT) ; recombinant human interleukin-1β was purchased from Fitzgerald 
Industries International (Concord, MA); poly(D, L-lactide-co-glycolide) 50:50 acid terminated 
polymers (2.5 A and 1 A inherent viscosity) were purchased from Evonik Industries 
(Birmingham, AL); collagenase was purchased from Worthington (Lakewood, NJ).; heparinized 
pig blood was purchased from Lampire Biological Laboratories (Pipersville, PA); poly(vinyl) 
alcohol, poly(ethylene-alt-maleic anhydride),  adenosine diphosphate, and all other chemicals 
and reagents were purchased from Sigma Aldrich (St. Louis, MO). 
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2.2. PLGA Particle Fabrication 
 PLGA microspheres were prepared using an oil-in-water emulsion evaporation 
technique.[1]  50:50 PLGA polymer with carboxylic acid terminal group was dissolved in 20 mL 
of dichloromethane (10 mg/mL)  and injected into 90 mL of aqueous buffer mixtures composed 
of 3 wt.% surfactant (95% poly(vinyl alcohol)/5% poly(ethylene-alt-maleaic acid) (PEMA), 
Table 4.1), 1% PEMA (Table 4.2), or 2% PEMA (Table 4.3) under mixing at 1,800 RPMs.  The 
emulsion mixed for 2 hours to allow for dichloromethane evaporation.  Differential 
centrifugation was utilized to wash and isolate microspheres with diameters between 2-3 µm.  
PLGA particles were then resuspended in water (3 mL) and instantaneously frozen in liquid 
nitrogen before drying using a lyophilized for 24-36 hours.  After drying, the particles were 
immediately used for avidin or PEG conjugation followed by use in flow assays.  Particles were 
imaged by brightfield microscopy using a Nikon TE-2000-S inverted microscope with a digital 
camera (Photometrics CoolSNAP EZ with a Sony CCD sensor) and the particle size measured by 
digital analysis using Metamorph® imaging software with a calibrated digital scale.  A sample 
image for PLGA spheres used in Chapter 4 is shown in Fig. 2.1. 
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Figure 2.1. Sample image of PLGA spheres used in Chapter 4. 
 
 
 
  
30 
2.3.  Fabrication of Polystyrene Rods 
 Polystyrene rods were fabricated using a polymer film stretching method.[2, 3]  2.1 µm 
polystyrene spheres were suspended in a 5% poly(vinyl alcohol) solution in a rectangular plastic 
tray and allowed to dry overnight.  The dried films were extracted from the tray and sliced into 
strips (2  cm x 6 cm or 2 cm x 4.5 cm for aspect ratio 4 or 9, respectfully) before being placed in 
an 1-dimensional stretching device composed of a parallel clamp system with one clamp 
movable and the other remaining stationary.  The stretching device was contained inside of an 
oven with a set temperature of 170°C.  The films were allowed to reach temperature for 20 
minutes before being stretched uniaxially to produce rods.  After stretching, the strips were 
soaked in a 30% isopropanol-water solution overnight to removed residual poly(vinyl alcohol).  
The rod solution was then washed and centrifuged multiple times with 30% isopropanol-water 
solution and dried overnight before imaging using a scanning electron microscope (SEM, 
Phillips XL30 FEG ESEM).  The aspect ratio (AR) was calculated by the ratio of the major axis 
length to the minor axis length measured from the imaged rods.  Sample images of 2 µm 
equivalent volume AR4 and AR9 rods are shown in Fig. 2.2. 
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(A)   AR4 Rods 
(B)   AR9 Rods 
Figure 2.2.  SEM images of (A) AR4 and (B) AR9 polystyrene 
rods used in Chapter 5. 
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2.4.  NeutrAvidin or PEG Attachment to Carboxylated Nano- and Microspheres 
NeutrAvidin or Amine-PEG-biotin was covalently coupled to carboxylated 
polystyrene/PLGA spheres or ellipsoids via carbodiimide chemistry.  Carboxylated particles 
were premixed with 0.2–5 mg/mL of amine-PEG-biotin or 5 mg/mL of NeutrAvidin in MES  
buffer (97.6 mg/mL) for 15 minutes; after which, equal volume (75 mg/mL) of N-(3-
Dimethilaminopropyl)-N’-ethylcarboiimide hydrochloride (EDAC) was added and the pH 
adjusted to 9.  The mixture was then incubated at room temperature for 20 hours at room 
temperature.  For PEGylated microspheres with high PEG density (~35,000 PEG chains/µm
2
, 
Chapter 4), particles were prepared and conjugated in MES buffer (97.6 mg/mL) with 0.6 M 
Na2SO4 for 20 hours at 60ºC.  After conjugation, PEGylated or NeutrAvidin spheres were 
thoroughly washed and stored in 50 mM phosphate buffered saline (PBS).    
 
2.5.  Ligand Attachment to NeutrAvidin or PEGylated VTCs 
 Biotinylated Sialyl Lewis
a
 (sLe
a
) or biotinylated human-anti-ICAM-1-mouse-IgG-1 
(aICAM-1) was incubated with the NeutrAvidin conjugated spheres and mixed end-over-end for 
45 minutes at room temperature with ligand concentrations corresponding to the desired ligand 
density (measured by flow cytometry).  For ligand attachment to PEGylated spheres, biotinylated 
ligands were first premixed with 20 µg/mL NeutrAvidin at an equal volume ratio for 20 minutes 
followed by incubation with PEGylated spheres (100 µL total volume) for 45 minutes at room 
temperature.[4]   For Collagen binding/vWF binding and cRGD peptides, NeutrAvidin coated 
polystyrene microsphere (2 µm) were incubated with 50-50 mixtures of CBP/VBP and cRGD (5 
µg/mL CBP/VBP and 5 µg/mL cRGD working concentrations) for 45 minutes at room 
temperature.  Ligated spheres were washed and stored in PBS buffer containing calcium and 
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magnesium ions and 1% bovine-serum-albumin (BSA).  
 
2.6.  Determination of PEG and Ligand Surface Density 
The surface densities of PEG and targeting ligands on spheres were characterized via 
flow cytometry (BD FACSCalibur, Life Technologies Attune, BD Quanta SC).  For 
measurement of microsphere PEG-biotin surface density, PEGylated spheres were stained with 
avidin-FITC at 10 µg/mL for 20 minutes at room temperature.  For FITC-loaded nanospheres, 
anti-biotin-PE was used for PEG-biotin surface density measurements.  For measurement of 
ligand surface density, anti-cutaneous lymphocyte antigen-PE or goat-anti-mouse IgG-FITC  
were used to label sLe
a
 or aICAM-1, respectfully.  Goat-anti-mouse IgG-PE was used to 
determine the site density of aICAM-1 on nanospheres.  Fluorescent intensities were converted 
to surface densities via a standard calibration curve, fluorescein-to-protein ratio, and microsphere 
surface area. 
 
2.7.  Characterization of PEG Corona 
 The conformation of the PEG corona was characterized by comparing the distance 
between adjacent PEG chains (S) to the Flory’s radius (Rf) given by the following equations: 
     
            [5] 
   √
 
 
         
where a is the length of one PEG monomer (0.35 nm), N is the number of PEG monomers 
obtained from the PEG molecular weight divided by the molecular weight of one PEG monomer, 
and A is the surface area occupied by one PEG chain calculated from the inverse of the PEG 
surface grafted density (# PEG chains/nm
2
).  The PEG corona conformation was estimated using 
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the following criteria (Fig. 2.3): [6] 
 
 
 
 
 
 
 
 
 
 
 
2.8.  Preparation of Endothelial Cell Monolayers 
Human umbilical vein endothelial cells (HUVECs) used in all adhesion assays were 
isolated from fresh umbilical cords (Mott Children’s Hospital, Ann Arbor, MI) via collagenase 
perfusion method pooled from multiple donate umbilical cords.[7]  HUVECs were cultured onto 
0.2 wt.% gelatin pretreated T-75 culture flasks with M199 medium composed of the following:  
10%  BCS, 10% FBS, 1% penicillin-streptomycin, 1% fungizone, 1% HEPES buffer, 1 µg/mL 
heparin 1% glutamine, and 50 µg/mL endothelial cell growth supplement.  For flow experiments, 
HUVECs were cultured onto 30 mm glass coverslips coated with 1% gelatin cross-linked with 
0.5% glutaraldehyde and 0.1 M glycine.   Coverslips with cultured cells were incubated at 37ºC 
and 5% CO2 to allow growth to confluency.[8]  Confluent monolayers were activated with 1 
ng/mL interleukin-1β (IL-1β) for 4 hours for E-selectin, 4 hours for ICAM-1 (Chapter 5), or 24 
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f
 
 Brush 
S << 2R
f
 
1 nm < S < 3 nm 
 
 
 
Intermediate-Brush 
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f 
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Figure 2.3.  Schematic orientation of the PEG corona as estimated by the 
relationship between the PEG spacer’s Flory’s Radius (Rf) and distance 
between adjacent PEG chains (S), as calculated by equations 2.1 and 2.2, 
respectfully.[6] 
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hours for ICAM-1 (Chapter 3) prior to use in adhesion assays. 
 
2.9.  Preparation of Collagen or vWF Surfaces 
 Flexiperm gaskets (1 cm x 2 cm) were placed on 30 mm glass coverslips in order to 
define the coverslip surface area prior to collagen or vWF surface coating.  30 mm glass 
coverslips were coated with vWF or denatured collagen (500 µg/mL) prepared in PBS buffer or 
0.2 M acetic acid, respectfully, and coated onto the defined surface area for 2 hours with gentle 
shaking at room temperature.  The protein solution was then removed and the coated area rinsed 
twice with PBS buffer (with calcium and magnesium ions).  In order to minimize non-specific 
interaction between blood cells and non-coated glass, the defined coverslip area was then coated 
with 3% denatured BSA for a minimum of 1 hour and until use in flow assay.  Before use in flow 
assay the BSA solution was removed and coverslip rinsed twice with PBS buffer (with calcium 
and magnesium ions). 
 
2.10.  Blood Preparation 
 For human whole blood assays (Chapters 3-5), fresh human blood was obtained via 
venipuncture according to a protocol approved by the University of Michigan Internal Review 
Board and in line with the standards set by the Helsinki Declaration.[9]  Appropriate informed 
consent was obtained from human subjects.  Venous blood was collected from healthy adults 
into a syringe containing citric acid-sodium citrate-dextrose (ACD) as anticoagulant.   
 For pig blood preparation (Chapter 4), unspecified Na heparinized pig blood was 
purchased from Lampire Biological Laboratory (Pipersville, PA).  Whole blood was centrifuged 
at 1,000 g for 30 minutes in order to separate the RBCs from platelet rich plasma.  The leukocyte 
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buffer layer at the RBC-plasma interface was discarded to remove leukocytes.  Pig RBCs were 
washed 3 times with cold PBS buffer (no calcium or magnesium ions) at 1,000 g for 30 minutes.  
Pig platelets were separated from plasma by centrifuging the platelet-rich-plasma at 2,250 g for 
25 minutes.  Pig RBCs were reconstituted in flow buffer (PBS buffer with 1% BSA with calcium 
and magnesium ions) or viscous buffer (flow buffer with 2 wt.% dextran) at the same 
hematocrits (volume % RBCs) as pig whole blood.  Pig whole blood samples were not treated 
with centrifugation.  All blood samples were pre-warmed to 37°C before use in flow assay. 
For reconstituted blood used in Chapter 6, human whole blood was centrifuged twice at 
300 g for 10 minutes to isolate red blood cells from plasma containing leukocytes and platelets.  
The platelet and leukocyte plasma was centrifuged at 300 g for 10 minutes to removed 
leukocytes from platelet-right-plasma which was then centrifuged at 1,000 g for 10 minutes to 
isolate platelets.  Platelets were washed with CGS buffer (120 mM sodium chloride, 13 mM 
sodium citrate, 30 mM glucose) containing PGE1 (75 nM).  After washing, platelets where 
resuspended in Tyrodes Buffer (500 mL DI-water, 4.095 g NaCl, 0.1 g KCl, 0.505 g NaHCO3, 
0.0275 g NaH2PO4, and 0.4955 g Glucose) and stored at room temperature.  Platelets were 
stained with calcein green AM  (2.5 µM in DMSO) for 20 minutes and washed three times with 
CGS buffer with PGE before adding platelets to reconstituted blood and perfused through the 
flow channel. 
 
2.11.  Flow Adhesion Assay Setup 
 A parallel plate flow chamber (PPFC, Glycotech) was used for all in vitro flow adhesion 
assays.  The PPFC was equipped with tygon tubing for the inlet feed, outlet, and vacuum lines.  
A rectangular silicon gasket (2 cm x 1 cm x 0.0254 cm) was placed on the PPFC to define the 
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flow channel.  Activated HUVEC cultured onto coverslips were placed onto the PPFC (cell side 
up onto the gasket, i.e. PPFC on top of culture HUVEC monolayer) and held in place via 
vacuum.  The flow channel was gently rinsed with PBS flow buffer (with calcium and 
magnesium ions and 1% BSA) to removed air bubbles and cell debris prior to the start of the 
flow assay.  Ligand-coated spheres were added to blood at various concentrations (5x10
5
 
particles/mL for Chapters 3, 4, and 6; 5x10
5
 – 1x107 particles/mL for Chapter 5) and perfused 
over the activated monolayer using a programmable syringe pump (KD Scientific, model no. 
780212, Holliston, MA).  All flow adhesion assays where conducted at 37°C.  After the flow 
assay, the monolayer was rinsed with flow buffer and the monolayer imaged using a Nikon TE-
2000-S inverted microscope with a digital camera (Photometrics CoolSNAP EZ with a Sony 
CCD sensor).  Sample images of HUVEC monolayer with particles are shown in Fig 2.4.  For 
the microchannel flow assays (Chapter 3), a polydimethylsiloxane (PDMS) flow channel was 
cast from a designed template as previously described.[10]  The microchannel used in the flow 
assays in Chapter 3 was fabricated by Katawut Namdee from the Eniola Lab.  
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(B) 
 
Leukocyte 
(A) 
5 µm Targeted Spheres 
2 µm Targeted Sphere Platelets 
Figure 2.4.  Sample images of HUVEC monolayer after flow adhesion assay of 
(A) whole blood oscillating flow with 5 µm sLe
a
-targeted spheres and (B) 
reconstituted blood flow with platelets (green) and 2 µm sLe
a
-targeted spheres 
(dark gray).   
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2.11.1.  Laminar Flow Assay 
The WSR (γw) or all laminar flow assays was fixed by controlling the volumetric flow 
rate (Q) according to the following equation: 
   
  
   
          
where Q is the volumetric flow rate (mL/min), h is the channel height (0.0254 cm for all flow 
assays), and w is the channel length (1 cm). 
 
2.11.2.  Oscillating Flow Assay 
 Flow oscillating flow assays (Chapter 5), the flow through the channel was controlled by 
a programmable pump with the following flow conditions:  (1) 1.29 mL/min for 8 seconds to fill 
the chamber with blood, (2) forward flow at 6.45 mL/min (1,000 s
-1
 WSR) for 14 seconds, (3) 
reverse flow for 6.45 mL/min (1,000 s
-1
 WSR) for 7 seconds, (4) 3.225 mL/min (500 s
-1
 WSR) 
until the HUVEC surface was imaged.  Steps (2) and (3) were looped and allowed to cycle for a 
total of 15 minutes (5 minutes of forward flow at 1,000 s
-1
 WSR).  Oscillating flow profile was 
previously confirmed by tracking the average velocity of tracking particles as shown in Fig. 2.5.   
[11] 
 
 
Figure 2.5.  Average velocity profile for oscillating blood flow.[11] 
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2.12.  Data Analysis and Statistics 
 Particle adhesion was normalized to the imaged surface area (0.152 mm
2
) in order to 
obtain the particle adhesion density (#/mm
2
).  The HUVEC surface was imaged at various widths 
along the center of the define flow channel in order to account for variation in the adhesion 
across the monolayer.  Particles were considered firmly adherent if the particle was stationary for 
at least 10 seconds.  Each data bar in chapter figures represents a minimum of three trials from 
different donors which include at least ten fields-of-view per experiment.  Binding efficiency in 
Chapter 3 was calculated by dividing the average particle adhesion density by the total number 
of particles fed in the flow chamber for a fixed WSR.  For leukocyte adhesion in Chapter 5, the 
leukocyte adhesion density in blood flow containing targeted spheres was normalized to the 
leukocyte adhesion density in particle-free blood from the same human donor; where a value of 1 
indicates no change in leukocyte adhesion density in particle containing blood flow relative to 
particle free blood.  All data is plotted with its corresponding standard error.  Statistical 
significance was determined using a student t-test, one-way ANOVA with turkey post-test, and 
one-way ANOVA with Bonferroni’s multiple comparison test (Chapter 5).  Differences were 
considered statistically significant is p<0.01 (i.e. α=0.01 for all statistical tests). 
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CHAPTER 3  
 
EFFECT OF PEGYLATION ON THE LIGAND-BASED TARGETING OF DRUG 
CARRIERS TO THE VASCULAR WALL IN BLOOD FLOW 
 
 
Contents of this chapter have been published as: 
 
Onyskiw, P.J. and Eniola-Adefeso, O.  Langmuir, 2013. 29(35):  p.11127-11134. 
 
 
 
3.1.  Introduction 
A major challenge for systemic circulating vascular-targeted carriers (VTCs) is the 
avoidance of the immune response; specifically, the avoidance of plasma protein adsorption onto 
the VTC’s surface which initiates systemic clearance.  To date, the most common method used 
to prevent protein adsorption is PEGylation - the modification of a carriers’ surface with 
poly(ethylene glycol) (PEG).  The hydrophilic nature of PEG helps inhibit plasma proteins from 
adsorbing onto the carrier’s surface, resulting in an increase in the carrier’s systemic circulation 
time.[1]  Increasing VTC circulation time in turn improves the passive targeting ability of drug 
carriers to areas such as cancerous tumors, the lungs, liver, and the brain.[2, 3]   
Many of the passive targeting (tissue targeting by physical entrapment) benefits from 
PEGylation, including increased circulation time, are dependent on the orientation of the PEG 
corona.[4, 5]  Improved circulation time is typically achieved when the PEG spacers are oriented 
in a brush conformation, where the PEG chains protrude away from the carrier’s surface rather 
than the mushroom orientation where the chains are entangled and remain close to the carrier’s 
surface.  Achieving the brush versus mushroom conformation is dependent on both the PEG 
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molecular weight and grafting density, with lower molecular weight chains requiring higher 
surface grafted densities to achieve the brush orientation than larger molecular weight chains.[6, 
7]  Surfaces with PEG molecular weights greater than 3.4 kDa with 2-5 mole % surface coverage 
have been shown to be sufficient conditions for preventing protein adsorption.[4, 8]  However, to 
date, it is not clear what effect PEGylation has on the ligand-based adhesion of VTCs to the 
vascular wall in human blood flow.  
Overall, the effectiveness of VTCs is dependent on the following: the carrier’s (1) ability 
to migrate from the center of bulk blood flow and localize to the blood vessel wall, and (2) 
capacity to specifically target and adhere to the endothelium in the diseased tissue.  VTC 
localization to the blood vessel wall is dependent on carrier parameters such as size, shape, and 
hemodynamics.[9-12]  Tissue-specificity typically requires modifying the carrier’s surface with 
adhesive ligands whose counter-receptors are upregulated during a diseased state.  For 
PEGylated VTCs this would often entail attaching the adhesive ligand to the free end of the PEG 
spacer, which has been shown to alter the receptor-ligand dynamics.  For example, the binding 
distance of a biotin-avidin system was previously shown to increase with PEGylated biotin and 
was a function of the PEG molecular weight.[13, 14]  PEG molecular weight and grafted density 
were also shown to influence ligand induced cellular adhesion and internalization.[15, 16]  
Similarly, PEGylation improved the binding dynamics of ligands to their counter receptors in 
shear flow by decreasing bond stress and increasing the frequency of binding in a low shear 
saline laminar flow system (~100 s
-1
 wall shear rate).[17].  However, it is unclear if improved 
adhesive dynamics with PEGylation translates to an increase in VTC adhesion to an inflamed 
endothelium in blood, which is dependent on both the adhesive interactions of the targeting 
system and VTC margination in blood.[17]   
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VTC margination in blood has previously been shown to be strongly dependent on the 
carrier size in the particles <1 µm in diameter do not marginate and adheres to the vascular wall 
as well as 2 µm and 5 µm targeted spheres.[11, 18]  Submicron spheres (0.2–1 µm in diameter) 
are of particular interest for vascular targeting due to their ability to remain in systemic 
circulation longer than microspheres.[19]  The targeting ability of submicron spheres in small 
vessels is also of particular interest in treating cancerous tumors, as tumor microvasculature is 
similar in size to arterioles and venules (20–100 µm in diameter).[20]  Inflammation targeting 
submicron spheres were previously shown to exhibit significantly lower adhesion densities in 
blood flow compared to microspheres (2 µm and 5 µm) in both large flow channels (>125 µm 
channel height) and small microchannels (28 µm and 50 µm channel heights).  This was 
attributed to the submicron sphere’s poor localization to the endothelial wall in blood flow.[10, 
11]  With the addition of a PEG spacer, the targeting ligand is moved away from the carrier’s 
surface and is inherently presented closer to the targeted receptors expressed on the endothelium.  
However, it is unknown if PEGylation will enhance the nanosphere adhesion in blood, 
particularly in vessels with diameters similar to the microvasculature of cancerous tumors.  
In this work, I examine the effect of different size PEG spacers (2.3 kDa, 5.5 kDa, and 10 
kDa) on the adhesion of 2 µm and 500 nm polystyrene spheres to activated human umbilical vein 
endothelial cell (HUVEC) monolayer from human blood at physiological shear rates.  The effect 
of PEG molecular weight and surface density was examined using two receptor-ligand systems 
commonly explored for targeting endothelial inflammation; E-selectin/Sialyl Lewis
a 
(sLe
a
) and 
intercellular adhesion molecule-1 (ICAM-1)/anti-intercellular adhesion molecule-1 (aICAM-
1).[21]  The results show that PEG spacers improved, diminished, or did not affect the adhesion 
efficacy of VTCs in blood depending on the PEG size and surface density, and the nature of the 
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specific receptor-ligand kinetics employed.   
 
3.2. Results 
 The experimental setup used in this chapter is described in detail in Chapter 2. 
 
3.2.1. Effect of PEG on sLea Mediated Adhesion 
In order to investigate the effect of PEG molecular weight on particle adhesion to 
activated endothelial cells (ECs), 2.3 kDa, 5.5 kDa, and 10 kDa PEG spacers were conjugated 
onto 2 µm spheres at surface densities that correspond to an extended brush conformation for 
each of the PEG sizes.  A PEG brush conformation was estimated using the Flory’s radius, Rf.  A 
brush conformation occurs when the distance between adjacent PEG chains (S), estimated based 
on the PEG surface density, falls between Rf and 2Rf (Rf< S< 2 Rf), i.e. chain overlap Rf/S>½, 
(Fig. 2.3).[1, 17]  An Rf of 4.4 nm, 7.7 nm, and 11.3 nm with chain overlaps of 63%, 92%, and 
72% were used to achieve an extended brush conformation for the 2.3 kDa, 5.5 kDa, and 10 kDa 
PEGylated microspheres, respectfully (Table 3.1).  It is worth noting that it is possible that the 
multivalent probes used for determining PEG densities used in the chain overlap calculations 
may underestimate the PEG surface density, particularly for larger PEG chains that have more 
mobility on the surface and hence a higher chance of multiple chains reacting with a single 
multivalent probe.  However, there was good agreement in the measured site density for the high 
molecular weight PEG chains on 2 µm spheres when probed with the avidin-FITC versus the 
anti-biotin-PE probe (Table 3.2). 
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Table 3.1.  PEG density, Rf, approximate distance between adjacent PEG chains (S), and 
PEG corona conformation as estimated by Rf < S< 2Rf. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
PEG Molecular 
Weight 
2.3 kDa PEG 5.5 kDa PEG 10 kDa PEG 
PEG Density 
(chains/µm
2
) 
25,000 ± 2,300 18,440 ± 50 5,200  ± 300 
Rf  (nm) 4.4 7.7 11.3 
2Rf  (nm) 8.8 15.4 22.6 
S (nm) 7.1 8.3 15.7 
Estimated 
Conformation 
Intermediate 
Brush 
Intermediate 
Brush 
Intermediate 
Brush 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.    Comparison of 5.5 kDa and 10 kDa PEG surface density on 
2 µm spheres measured with avidin-FITC and anti-biotin-PE 
 
 
5.5 kDa PEG 
(PEG chains/µm
2
) 
10 kDa PEG 
(PEG chains/µm
2
) 
Avidin-FITC 14,800 ± 100 5,520 ± 12 
anti-Biotin-PE 12,200 ± 1,100 5,270 ± 90 
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 Fig. 3.1.A shows the adhesion of sLe
a
-coated spheres with PEG spacers in the brush 
conformation as a function of channel WSR for a fixed sLe
a
 (targeting ligand) density of 1,000 
sites/µm
2
.  There was no significant difference in the adhesion density between the non-
PEGylated and PEGylated sLe
a
-spheres for all PEG molecular weights at each of the WSRs 
evaluated.  The PEG brush densities used for assays in Fig. 3.1.A were set based on the 
maximum average density achievable on the 2 µm spheres for each PEG size.  To determine 
whether the lack of a significance difference in adhesion between sLe
a
-targeted spheres of 
different PEG molecular weights was a result of the differences in the actual PEG density on the 
particle surface, I evaluated the adhesion of 5.5 kDa and 10 kDa PEGylated sLe
a
-spheres at a 
fixed PEG brush density of ~5,200 PEG chains/µm
2
 and a fixed sLe
a
 density of 1,000 sites/µm
2
.  
As shown in Fig. 3.1.B, the adhesion density for the 5.5 kDa PEG sLe
a
-spheres was not 
significantly different from that of 10 kDa PEG sLe
a
-spheres at the fixed PEG density (p=0.1097 
and p=0.0389 for 200 and 1,000 s
-1
, respectfully).   Overall, the adhesion of both non-PEGylated 
and PEGylated sLe
a
-spheres increased with increasing WSR.  This observation is expected for 
sLe
a
-mediated adhesion of 2 µm spheres in blood flow for the ligand density used based on our 
previous publication and is due to the normal force impacted by the red blood cells (RBCs) 
aiding the particles at the wall in overcoming the increase in shear force associated with an 
increase in WSR, i.e. an increase in the WSR in the absence of a corresponding increase in 
disruptive force results in higher adhesion.[9]  Also, control experiments with non-targeted 
PEGylated spheres resulted in no adhesion to the EC monolayer, confirming that the actual 
particle adhesion shown in Fig. 3.1 was mediated by the interaction of targeting ligand (sLe
a
) 
with its EC-expressed receptor(s) (data not shown). 
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Figure 3.1.  (A) Adhesion of sLe
a
 (1,000 sites/µm
2
) PEGylated 2 µm spheres to an activated 
ECs in laminar whole blood flow as a function of PEG size and channel wall shear rate. (b) 
Adhesion of 5.5 kDa and 10 kDa-PEGylated 2 µm spheres in laminar whole blood flow for a 
fixed PEG density of 5,200 PEG chains/µm
2
 and sLe
a
 density of 1,000 sites/µm
2
. 
 
 
 
  
 
49 
To investigate the effect of PEG conformation on the adhesion of sLe
a
-targeted spheres in 
blood, 5.5 kDa PEG was conjugated to the surfaces of 2 µm spheres at either a low or high 
surface density of approximately 3,500 ± 300 or 11,000 ± 200 chains/µm
2
, which were estimated 
to correspond to a mushroom (chain overlap = 40%) or an intermediate-brush conformation 
(chain overlap = 72%), respectfully.  At 200 s
-1
, there was no difference in adhesion between 
non-PEGylated and PEGylated sLe
a
-spheres for both PEG conformations at this PEG molecular 
weight (Fig. 3.2.A).  At 500 s
-1
, the adhesion of the PEG-Mushroom spheres was slightly lower 
than the adhesion of the non-PEGylated spheres, but there was no significant difference in 
adhesion between non-PEGylated spheres and the PEG-Brush spheres.  For the 1,000 s
-1
 WSR, 
the adhesion of PEG-Mushroom spheres was approximately 4.5-fold lower than both the non-
PEGylated and PEG-Intermediate-Brush spheres.  There was no significant difference in 
adhesion between the non-PEGylated and the PEG-Intermediate Brush spheres.  A similar assay 
with 2.3 kDa PEGylated sLe
a
-targeted spheres shows the same trend for particle adhesion at 
1,000 s
-1
 where the adhesion of microspheres with a low PEG density of ~12,800 PEG 
chains/µm
2
 (chain overlap = 44%; PEG-Mushroom) was 3-fold lower than the adhesion of 
particles with a high PEG density of 26,800 PEG chains/µm
2 
(chain overlap = 63%; PEG-
Intermediate-Brush) and ones that were non-PEGylated (Fig. 3.2.B). 
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Figure 3.2.  Adhesion of (A) 5.5 kDa PEG-Mushroom (3,500  PEG chains/µm
2
) and PEG-
Intermediate Brush (11,000 PEG chains/µm
2
) and (B) 2.3 kDa PEG-Mushroom (12,800 PEG 
chains/µm
2
) and PEG-Brush (26,800 PEG chains/µm
2
) 2 µm spheres targeted with 1,000 
sLe
a
/µm
2 
to activated ECs in laminar whole blood flow as a function of channel wall shear 
rate (WSR). * indicates p<0.01 when compared to the adhesion of non-PEGylated spheres at 
the same WSR and # indicates p<0.01 when compared to the adhesion of PEG-Mushroom 
spheres (of the same molecular weight) at the same WSR. 
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3.2.2. Effect of PEG on aICAM-1 Mediated Adhesion 
To investigate whether targeting ligand type influences the adhesion of PEGylated 
spheres, 2 µm PEGylated and non-PEGylated spheres were conjugated with approximately 2,600 
sites/µm
2
 of anti-ICAM-1 (aICAM-1) antibody to target ICAM-1.  Fig. 3.3.A shows the adhesion 
to activated ECs in blood flow of aICAM-1 spheres containing 2.3 kDa, 5.5 kDa, and 10 kDa 
PEG spacers in an intermediate-brush conformation, at the respective PEG densities reported in 
Table 3.1, as a function of channel WSR.  At 200 s
-1
, there was no significant difference in 
adhesion between the PEGylated and non-PEGylated aICAM-1-spheres.  At 500 s
-1
, the adhesion 
of non-PEGylated aICAM-1-spheres was approximately 7-fold lower than the adhesion of all 
PEGylated spheres and no difference in adhesion was observed between the different PEGylated 
spheres.  At 1,000 s
-1
, no adhesion was observed for non-PEGylated aICAM-1 spheres and the 
level of adhesion observed for the 2.3 kDa PEG-Brush spheres was 2.8-fold lower than the 
adhesion of 5.5 kDa and 10 kDa PEG-Brush spheres.  There was no significant difference 
between the adhesion of 5.5 kDa and 10 kDa PEGylated spheres.  As with sLe
a
-targeting, there 
was no significant difference in adhesion between the 5.5 and 10 kDa PEG microspheres when a 
fixed PEG brush density of ~5,200 PEG chains/µm
2
 was used at a fixed sLe
a
 density of 1,000 
sites/µm
2
 (data not shown). 
To determine whether the higher adhesion of PEGylated aICAM-1-spheres with 
increasing channel WSR was due to improved adhesion kinetics, particle adhesion density was 
normalized to the total number of particles perfused through the flow channel at a fixed WSR, 
i.e. fraction of total perfused particle that was bound (adhesion efficiency).  Fig. 3.3.B shows the 
adhesion efficiency of PEGylated and non-PEGylated spheres at different WSRs as a function of 
PEG molecular weight (Table 3.1).  The adhesion efficiency for non-PEGylated spheres 
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significantly decreased with increasing WSR (compared to the efficiency of the same particles at 
200 s
-1
).  The adhesion efficiency of all the PEGylated spheres at 500 s
-1
 was not significantly 
different from the efficiency at 200 s
-1
,
 
suggesting that the improved adhesion density, relative to 
non-PEGylated spheres, was due to improved adhesive dynamics and not particle margination.  
However, the adhesion efficiency of all PEGylated spheres at 1,000 s
-1
 was significantly lower 
than the efficiencies of the same spheres at both 200 s
-1
 and 500 s
-1
. 
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Figure 3.3.  (A) Adhesion of aICAM-1 (2,600 sites/µm
2
) PEGylated microspheres to 
activated ECs in laminar whole blood flow as a function of PEG brush length at different 
wall shear rates (WSR).  * indicates p<0.01 when compared to the adhesion of non-
PEGylated spheres at the same WSR and ** indicates p<0.01 when compared to the adhesion 
of 2.3 kDa PEG spheres at the same WSR.  (B) Adhesion density normalized to the number 
of particles perfused at a given wall shear rate (Binding Efficiency).   # indicates p<0.01 
compared to the adhesion of the same particle at 200 s
-1
 and ## indicates p<0.01 compared to 
the adhesion of the same particle at 500 s
-1
. 
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To investigate the effect of PEG conformation on ICAM-1 targeting, 5.5 kDa PEG 
spacers were conjugated to the surface of 2 µm spheres at a low (3,500 ± 286 PEG chains/ µm
2
) 
or high PEG surface density (11,000 ± 219 PEG chains/µm
2
) estimated to be in a mushroom 
(40% chain overlap) or an intermediate-brush conformation (72% chain overlap), respectfully.  
There was no significant difference in adhesion between the non-PEGylated and PEGylated 
aICAM-1-spheres with both conformations at 200 s
-1 
(Fig. 3.4).  At 500 s
-1
, the adhesion of non-
PEGylated spheres was 4.5- and 8.6-fold lower than the adhesion of PEG-Mushroom and PEG-
Intermediate-Brush spheres, respectfully.  At this same WSR, the adhesion of the PEG-
Mushroom spheres was 2.0-fold lower than the adhesion of PEG-Intermediate-Brush spheres.  At 
1,000 s
-1
, there was no adhesion observed for non-PEGylated spheres and minimal adhesion for 
the mushroom-oriented PEG spheres.  The adhesion of the PEG-Intermediate Brush spheres 
1,000 s
-1
 was 9.6-fold higher than that of the PEG-Mushroom spheres at 1,000 s
-1
 WSR. 
To determine if improving the adhesion kinetics for non-PEGylated spheres (via 
increasing aICAM-1 site density) would increase their adhesion density to the level of 
PEGylated spheres, the adhesion of non-PEGylated spheres with 4,400 sites/µm
2
 aICAM-1 
density (Fig. 3.4; solid black bars) was compared to the adhesion of non-PEGylated and 
PEGylated spheres with 2,600 aICAM-1 sites/µm
2
.  At 200 s
-1
, the adhesion density of the higher 
aICAM-1-density non-PEGylated spheres was 1.8-fold higher than all the spheres with 2,600 
aICAM-1 sites/µm
2
.  At 500 s
-1
 WSR, the adhesion of the higher aICAM-1 density spheres was 
8.0- and 1.7-fold higher than the adhesion of non-PEGylated and PEG-Mushroom spheres, 
respectfully; however, there was no significant difference in the adhesion density between the 
PEG-Intermediate-Brush spheres and the higher aICAM-1 density non-PEGylated spheres.  With 
1,000 s
-1
 WSR of laminar blood flow, the adhesion of the high aICAM-1 density spheres was 
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5.0-fold lower than the PEG-Intermediate Brush spheres, and there was no significant difference 
in adhesion between the higher aICAM-1 density-spheres and the PEG-Mushroom spheres.  No 
adhesion was observed for non-PEGylated spheres with 2,600 aICAM-1 sites/µm
2 
at 1,000 s
-1 
WSR. 
 
 
Figure 3.4.  Adhesion of 5.5 kDa PEG-Mushroom (3,500  PEG chains/µm
2
) and PEG-
Intermediate-Brush (11,000 PEG chains/µm
2
) 2 µm spheres targeted with 2,600 aICAM-1 
sites/µm
2
 to activated ECs in laminar whole blood flow as a function of channel wall shear 
rate (WSR). * indicates p<0.01 when compared to the adhesion of non-PEGylated spheres at 
the same WSR, ** indicates p<0.01 when compared to the adhesion of PEG-Mushroom 
spheres at the same WSR, and # indicates p<0.01 when compared to the adhesion of non-
PEGylated spheres with 4,400 aICAM-1 sites/µm
2
 and the same WSR. 
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3.2.3. Effect of PEGylation on Targeted Nanosphere Adhesion 
To determine whether the effect of PEG spacers on particle adhesion was affected by 
particle size, I investigated the adhesion of 500 nm spheres conjugated with a 5.5 kDa PEG 
spacer oriented in the brush conformation (~16,000 PEG chains/µm
2
, intermediate-brush 
conformation) and targeted with either sLe
a
 or aICAM-1 (1,000 sites/µm
2 
and 2,600 sites/µm
2
, 
respectfully).  As shown in Fig. 3.5.A, there was no significant difference in adhesion between 
PEGylated and non-PEGylated sLe
a
-spheres at the three WSRs explored, similar to observations 
with the 2 µm sLe
a
-spheres.  The adhesion of both PEGylated and non-PEGylated 500 nm sLe
a
-
spheres increased with increasing WSR between 200 and 500 s
-1
; however, there was no 
significant increase in adhesion for both nanosphere types between 500 and 1,000 s
-1
.  Increasing 
the PEG size to 10 kDa on the sLe
a
-targeted spheres did not significantly alter the adhesion 
compared to both the non-PEGylated and 5.5 kDa PEGylated submicron spheres (data not 
shown).  When targeted with aICAM-1, there was no significant difference between the adhesion 
of PEGylated and non-PEGylated 500 nm spheres in blood flow at 200 s
-1
 (Fig. 3.5.B), similar to 
the observation with sLe
a
 spheres.  However, at 500 s
-1
 and 1,000 s
-1
 the adhesion of 5.5 kDa 
PEGylated spheres was significantly higher than non-PEGylated spheres.  There was no 
significant difference in adhesion between the PEGylated spheres at 500 and 1,000 s
-1
.  Overall, 
the adhesion of the 500 nm spheres was 4- and 17-fold lower than the adhesion of the 2 µm 
spheres at the same blood particle concentration for similar PEG conditions and the WSRs 
evaluated.  I also investigated whether PEGylation aided in the capture and adhesion of 
submicron spheres in blood flow through a microchannel (28 µm channel height).  The results 
were similar to what was observed in the larger (254 µm channel, Fig. 3.5.) in that PEG had no 
significant effect on the adhesion of sLe
a
-targeted submicron spheres (Fig. 3.6.A) and slightly 
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increased the adhesion of aICAM-1 targeted submicron spheres (Fig. 3.6.B), but only at 500 s
-1
 
WSR.   
 
Figure 3.5.  Adhesion of (A) sLe
a
 (1,000 sites/µm
2
)-PEGylated and (B) aICAM-1 (2,600 
sites/µm
2
)-PEGylated 500 nm spheres to activated ECs in laminar whole blood flow at 
different wall shear rates. * Indicates p<0.01 when compared to non-PEGylated spheres at a 
fixed WSR. 
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Figure 3.6.  Adhesion of (A) sLe
a
 (1,000 sites/µm
2
)-PEGylated and (B) aICAM-1 (2,600 
sites/µm
2
)-PEGylated 500 nm spheres to activated ECs in laminar whole blood flow through 
a microchannel. * Indicates p<0.01 when compared to non-PEGylated spheres at a fixed 
WSR. 
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3.3.  Discussion 
The addition of PEG onto a carrier’s surface is an effective strategy for sterically 
reducing protein adsorption and increasing systemic circulation time.[2, 4]  However, it is 
unclear if the addition of PEG spacers has an effect on ligand-based adhesion of VTCs to the 
vascular wall in blood flow at physiological WSRs.  In this work I investigated the effects of (1) 
PEG corona size for the case where PEG chains were in the more extended brush conformation 
and (2) PEG conformation (i.e. high versus low PEG surface density) on VTC adhesion for both 
sLe
a
 and aICAM-1 targeted spheres.  Overall, I show that the addition of PEG spacers did not 
hinder particle adhesion in human blood flow when the VTCs are grafted with a high PEG 
surface density corresponding to an intermediate brush conformation.  However for blood flow at 
high WSR (1,000 s
-1
), a low-density PEGylation, where the PEG chains are estimated to be 
oriented in a more entangled mushroom conformation (S>Rf or chain overlap <50%), resulted in 
reduced adhesion for VTCs compared to the higher PEG density brush spheres irrespective of the 
ligand type (Fig. 3.2 and Fig. 3.4).  
The addition of a PEG spacer in the intermediate-brush conformation was found to 
improve the adhesion of 2 µm
 
spheres at intermediate and high WSRs (500 s
-1
 and 1,000 s
-1
) 
when the targeting ligand was aICAM-1.  This observation is in agreement with a previous report 
by Ham and coworkers where they showed that the flexibility of the PEG chains improved the 
ligand adhesion kinetics, and hence adhesive flux, of targeted microspheres for monovalent 
receptor-ligand systems in low saline flow (~100 s
-1
 WSR) by reducing the bond stress.[17]  
They also showed that the improved kinetics was dependent on PEG molecular weight.[17]  
Interestingly, the results showed that increasing the surface density of aICAM-1 on the non-
PEGylated spheres can improve the adhesion to levels observed for PEGylated spheres at an 
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intermediate WSR (500 s
-1
).  It is anticipated that a further increase in aICAM-1 density without 
PEG would restore adhesion at higher WSRs (e.g. 1,000 s
-1
) to the level seen for PEGylated 
spheres at the low ligand density.  It may be difficult to achieve such higher ligand density due to 
steric hindrance that can occur with a high concentration of ligand present in the conjugation 
medium, resulting in surface saturation.  Contrary to Ham and coworkers, there was no 
significant difference in aICAM-1 microsphere adhesion with the various PEG sizes at the low to 
intermediate WSRs (200 s
-1 
and 500 s
-1
) evaluated (Fig. 3.3), which was likely due to the 2 µm 
spheres used in this work experiencing lower drag forces compared to the 5 µm spheres 
evaluated by Ham and coworkers.  Indeed, when 2 µm spheres were observed at high WSR 
(1,000 s
-1
), the PEG size was found to be important where the adhesion of the 2.3 kDa-
PEGylated aICAM-1 microspheres was found to be significantly lower than the adhesion of 
particles with larger PEG size (Fig. 3.3).  This suggests that there is a minimum PEG size 
requirement for PEG spacers to reduce the bond stress in high shear flow, where microsphere 
adhesion is reaction limited and stronger adhesion kinetics is necessary as is the case for 
monovalent ICAM-1 targeting.   
While Ham and coworkers only focused on monovalent interactions, the addition of PEG 
to multivalent sLe
a
 coated spheres used in this work did not improve microsphere adhesion in 
blood flow.  This suggests that an increase in microsphere adhesion from PEGylation is 
dependent on the baseline adhesion characteristics of the targeting ligand systems.  SLe
a
 has 
been previously reported to exhibit a fast on-rate (rate of forward reaction) to E-selectin 
underflow conditions which makes this receptor-ligand system very efficient at mediating the 
capture of particles to the endothelium from flow in the absence of PEG, unlike the slow reaction 
kinetics for the aICAM-1-ICAM-1 system evaluated here.[22-24]  It is anticipated that the 
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presence of a PEG spacer would progressively be important for microspheres adhesion with sLe
a
 
ligand at lower ligand densities and/or at very high WSRs where the probability of receptor-
ligand interaction is drastically reduced. 
The data presented in Fig. 3.2 and Fig. 3.4 shows that PEG surface density significantly 
influences microsphere adhesion with both targeting ligands evaluated, particularly at 500 s
-1
 
(aICAM-1) and 1,000 s
-1
 (aICAM-1 and sLe
a
) where microsphere adhesion is reaction limited 
and highly dependent on ligand density and availability.  The decrease in adhesion with the low 
density PEG spheres (where the PEG corona is estimated to be in a more entangled mushroom 
conformation based on the S > 2Rf) is likely due to poor ligand presentation and steric repulsive 
forces as a result of the PEG corona length being similar to its equilibrium length, Rf.  When the 
PEG spacers are oriented in a more extended brush conformation (Rf < S), the targeting ligand is 
easily accessible for adhesion with its counter receptor resulting in an adhesion density 
equivalent or greater than the non-PEGylated spheres (depending on the targeting ligand) (Fig. 
3.2 and Fig. 3.4).  For both the 2.3 kDa and 5.5 kDa PEG-spheres at low PEG densities, the size 
of the PEG corona is equivalent to or slightly shorter than its corresponding Rf and hence a 
higher degree of PEG chain entanglement is anticipated.  Higher chain entanglement may then 
result in poor ligand presentation (i.e. decreased effective valency), which leads to a decrease in 
particle adhesion as observed for both targeting ligand systems evaluated.  Indeed, these findings 
are in agreement with previous works with bimodal systems (two PEG spacers of different 
lengths on a carrier’s surface) which have shown that when the targeting ligand is attached to a 
spacer that is significantly shorter than the Rf of the adjacent spacer, adhesion in static conditions 
is inhibited.[16, 26]  However, it may be that improving the ligand valency, via increasing ligand 
density, on a low-density mushroom-oriented PEG-sphere would be sufficient to increase 
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particle adhesion to the same level as the non-PEGylated and PEG-Brush spheres.  Increasing 
ligand density, however, may substantially affect tissue selectivity as was recently demonstrated 
by Zern et al., where nanospheres (~200 nm) with an aICAM-1 ligand density of 200 
antibodies/nanoparticle showed lower selectivity towards diseased pulmonary endothelium (in 
vivo) compared to nanospheres with only 50 antibodies/nanoparticle.[26]  Incidentally, Cruz et 
al. previously showed that the cellular internalization of 200 nm spheres targeted to dendritic 
cells with ligands grafted on a PEG spacer was most efficient (~70% of DC internalizing 
particles) when PEG sizes between 2-3 kDa were used compared to PEG sizes between 6 - 20 
kDa (~40 % of DC internalizing particles), suggesting that the shorter PEG sizes are preferable 
for situations where cellular internalization is critical.[15]  In this case, care must be taken to 
ensure that the amount of PEG grafted on particles is sufficient (i.e. S < 2Rf), to achieve all the 
targeting ligand in the appropriate orientation for targeting applications that involve blood flow 
adhesion prior to cellular internalization, since a higher PEG density is required to cross this 
threshold with smaller PEG sizes (e.g. ~16,000 PEG chains/µm
2
  for 2.3 kDa versus ~5,000 PEG 
chains/µm
2
 for 5.5 kDa by my estimation).   
To determine if the influence of PEG on VTC adhesion was particle size dependent, the 
effect of PEG spacers on the adhesion of 500 nm spheres was examined under similar conditions 
as 2 µm spheres.  Submicron spheres, rather than larger microspheres, were explored due to 
attractiveness for use as VTCs because of their ability to avoid capillary entrapment, thus 
potentially improving targeting efficiency.[19]  The addition of a PEG in an intermediate brush 
conformation did not significantly improve the adhesion density for sLe
a
-targeted 500 nm 
spheres in either larger flow channel (254 µm channel height) or microchannel (28 µm channel 
height) (Fig. 3.5. and Fig. 3.6.).  While there was a 7-fold increase in adhesion density for 
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ICAM-1 targeting of these particles at the intermediate to high WSRs in the larger channel (Fig, 
3.5.B), this increase in nanosphere adhesion was still minimal compared to the adhesion level 
observed for 2 µm spheres at the same WSRs (Fig. 3.3.A).  This discrepancy is most likely due 
to spheres < 1 µm not effectively marginating to the vessel wall and remaining entrapped in the 
RBC core during blood flow.[9-11, 18]  The data presented in this work suggests the addition of 
PEG most likely did not improve the localization of submicron spheres since the adhesion 
density of both PEGylated and non-PEGylated nanospheres remains substantially lower than that 
of 2 µm spheres under the same flow assay conditions similar to reports in previous 
publications.[9, 10, 18]        
In summary, the addition of a PEG corona to a VTC’s surface was shown to significantly 
affect VTC adhesion in blood flow.  While a low density PEG corona hinders adhesion under 
high shear condition, PEG with an extended intermediate-brush conformation can improve the 
adhesion of VTCs for targeting systems with adhesion dynamics similar to the aICAM-1/ICAM-
1 systems used in this work.  Based on these results, PEG spacers with molecular weights >5.5 
kDa with grafting densities corresponding to an intermediate-brush conformation or greater are 
recommend for maintaining or improving VTC adhesion in blood flow, particularly under high 
shear conditions such as those present in arteries susceptible to cardiovascular disease. 
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CHAPTER 4  
 
PEGYLATION TO IMPROVE THE ADHESION OF PLASMA-SENSITIVE DRUG 
DELIVERY SYSTEMS IN BLOOD 
 
Contents of this chapter are being prepared for manuscript submission (Namdee et al. In 
preparation. 2015).  Data from Fig. 4.2 has been published in the following: 
 
Sobczynski, D. J., Charoenphol, P., Heslinga, M. J., Onyskiw, P. J., Namdee, K., Thompson, A. 
J., and Eniola-Adefeso, O.  Plasma Protein Corona Modulates the Vascular Wall Interaction in 
a Material in a Donor Specific Manner, 2014.  PLoS ONE 9(9):  e107408. doi:  10. 
1371/journal.pone.010408. 
 
 
4.1.  Introduction 
 Tissue specific drug delivery entails loading a therapeutic agent into a drug delivery 
system (DDS) which targets diseased tissue through passive (physical entrapment) or active 
(ligand-based targeting) means.  While polystyrene spheres are often the choice as a model 
DDSs for optimizing the carrier’s margination and adhesion in blood, polystyrene itself is not 
applicable as DDSs due to the toxic nature of its precursor material.[1, 2]  Therapeutic release is 
dependent on the degradation of the DDS and thus, one of the key aspects in designing DDSs is 
to ensure that the DDS is biocompatible; that is to say, (1) the DDS’s core material itself is of 
low toxicity to the host and (2) the byproducts of degradation are absorbed into biological 
processes.  Poly(lactic-co-glycolic acid) (PLGA) is often proposed as a core material for 
polymeric DDSs due to its biocompatibility and approval for use as a DDS by the US Food and 
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Drug Administration; however, little work has been done demonstrating the adhesiveness of 
PLGA VTCs to the vessel wall in blood flow.[3]  
Recently, inflammation targeting PLGA microspheres were shown to have significantly 
lower adhesion levels in human blood compared to the adhesion in both buffer only and red 
blood cells-in buffer (RBCs+Buffer) systems.[4]  In fact, the adhesion of PLGA spheres in whole 
blood was reduced to 90-95% of the adhesion in RBCs+Buffer for a wide range of particle sizes 
(0.3-5 µm).[4]  This significant decrease in adhesion of PLGA targeted spheres in human blood, 
compared to buffer systems, was not observed with model polystyrene spheres in human 
blood.[4-6]  The reduction in PLGA adhesion was attributed to specific plasma proteins, within 
the 150 kDa molecular weight range, having a greater affinity for absorbing onto PLGA spheres, 
but not polystyrene spheres, and reducing the adhesiveness of the targeting ligand.[4]  
Interestingly, the magnitude of the reduction in PLGA adhesion in blood was donor specific, 
suggesting that VTCs may be less efficient in targeting the vessel wall in patients with greater 
concentrations of the impacting plasma protein(s).[4]  These results identified a material-specific 
plasma effect on VTC adhesion in blood which suggests that optimizing VTC adhesive trends 
using model polystyrene targeted spheres would not directly correlate to the adhesion of actual 
DDSs in blood.  
The observed plasma protein interference in vessel wall adhesion of DDSs also appears 
to extend to animal blood.  For instance, a plasma effect similar to that identified in humans has 
been observed in pig blood where targeted PLGA microspheres exposed to plasma (in 
RBC+Plasma only or pig whole blood) exhibited minimal adhesion to a model vessel under 
blood flow (Namdee et al. In preparation. 2015).  Interestingly, the adsorption of pig plasma 
proteins not only affected PLGA targeted spheres but also significantly reduced the adhesion of 
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model polystyrene targeted spheres in blood.  Pigs are often proposed as an in vivo model to 
study cardiovascular diseases due to pig blood and vasculature having similar reactivity, blood 
coagulation and atherosclerotic plaque formation, as humans.[7, 8]  Thus, the reduction in 
targeting ability from the adsorption of plasma proteins onto a DDS’s surface provides a 
limitation in optimizing both model (polystyrene-pig blood) and therapeutic (PLGA-human 
blood) DDSs in vitro and in vivo animal systems relevant to cardiovascular disease. 
One strategy for restoring or improving the adhesion of plasma sensitive DDSs 
(PLGA/human blood or polystyrene/pig blood) is to prevent the adsorption of plasma proteins 
onto the DDS’s surface.  As previously discussed in Chapters 1 and 3, PEGylation is a common 
strategy for reducing plasma protein adsorption onto a material’s surface.  This occurs due to the 
hydrophilic nature of PEG forming a water-shell around the polymer chain which sterically 
prevents plasma proteins from adsorbing onto a material.[9]  It is generally accepted that in order 
to achieve the steric hindrance required for preventing plasma protein adsorption, the PEG 
grafting density on the carrier’s surface must be high enough such that the PEG chains are 
extended away from the carrier’s surface (brush conformation).[9, 10]  However, there have been 
some reports of observing reduced plasma adsorption and its corresponding side effects, such as 
increased circulation time, using low PEG grafting densities or loop conformation in which both 
ends of the polymer spacer are attached to the particle’s surface.[11, 12]  Thus, PEG 
conformation alone is not a sufficiently descriptive criterion for preventing plasma protein 
adsorption due to the fact that the conformation of the PEG corona is dependent on both PEG 
molecular weight and grafting density.  It is also unclear whether improving the adhesion of 
plasma sensitive DDSs requires the complete prevention of all plasma proteins or simply 
reducing the adsorption of negatively impacting proteins (which were previously shown to be 
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approximately 150 kDa in molecular weight) onto the DDS’s surface.[4]  In this chapter, I 
examine if PEGylation can improve the adhesion of (1) sLe
a
-targeted PLGA microspheres in 
human blood, and (2) sLe
a
-targeted polystyrene microspheres in pig blood, which were both 
shown to have reduced adhesion due to the adsorption of plasma proteins, and work towards 
identifying a PEG density criterion for minimizing plasma effects and restoring adhesion for 
model and actual DDSs sensitive to plasma adsorption.  
 
4.2.  Results 
 The experimental set up used in this chapter is described in detail in Chapter 2. 
 
4.2.1.  Adhesion of PEGylated PLGA Targeted Microspheres in Human Blood 
 In order to investigate whether PEGylation would restore the adhesion of sLe
a
-targeted 
PLGA microspheres in human plasma systems (RBCs+Plasma or whole blood) to the level of 
adhesion in buffer systems (Buffer only or RBCs+Buffer), 5.5 kDa and 10 kDa PEG spacers 
were covalently attached to the surface of PLGA spheres prepared via an oil/water emulsion-
evaporation protocol as described in Chapter 2.  The 5.5 kDa and 10 kDa PEG spacers were 
chosen based on the results from Chapter 3, demonstrating that these PEG spacers in an 
intermediate-brush conformation did not significantly affect the adhesion of sLe
a
-targeted 
spheres (polystyrene) in human blood at the examined WSR (Fig. 3.1).  Tables 4.1 – 4.3 show 
the particle size, PEG surface density (and conformation), and sLe
a 
density for all PEGylated and 
non-PEGylated PLGA spheres used in Figs. 4.1. – 4.3.  The sLea density used in each experiment 
was based on the maximum sLe
a
 density achieved on the specific batch of PEGylated PLGA 
microspheres used in each flow assay. 
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Table 4.1.  PEG surface density (and conformation) and sLe
a
 density for particles 
used in Fig. 4.1. 
 
 
 
 
 
 
 
Table 4.2.  PEG surface density (and conformation) and sLe
a
 density for particles 
used in Fig. 4.2. 
 
 
 
 
 
 
 
 
Table 4.3.  PEG surface density (and conformation) and sLe
a
 density for particles 
used in Fig. 4.3. 
 
 
 
 
 
 
 PLGA-No PEG PLGA-5.5 kDa PEG 
Average Particle 
Diameter 
3.4 µm ± 1.2 µm 
PEG Density 
(PEG chains/µm
2
) 
- 
3,785 ± 361 
(mushroom) 
sLe
a
 Density 
(sites/µm
2
) 
453 ± 75 389 ± 122 
 
PLGA-No PEG PLGA-5.5 kDa PEG 
Average Particle 
Diameter 
3.0 µm ± 1.0 µm 
PEG Density 
(PEG chains/µm
2
) 
- 
16,092 ± 1,247 
(intermediate-brush) 
sLe
a
 Density 
(sites/µm
2
) 
1,750 ± 186 1,730 ± 144 
 PLGA-No PEG PLGA-10 kDa PEG 
Average Particle 
Diameter 
2.9 µm ± 0.2 µm 
PEG Density 
(PEG chains/µm
2
) 
- 
3,222 ± 183 
(intermediate-brush) 
sLe
a
 Density 
(sites/µm
2
) 
167 ± 53 171 ± 67 
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Fig. 4.1 shows the adhesion density of PEGylated PLGA spheres with a low PEG density 
corresponding to a mushroom conformation (3,800 PEG chains/µm
2
, Table 4.1) in human 
RBCs+Buffer, RBCs+Plasma, and whole blood under 200 s
-1
 WSR of laminar flow.  There was 
no significant difference in adhesion density between PEGylated and non-PEGylated PLGA 
particles in buffer-only flow.  The addition of RBCs to buffer increased the adhesion of both 
non-PEGylated and PEGylated PLGA spheres by 1.4- and 1.9-fold, respectfully.  The adhesion 
of PEGylated PLGA spheres in RBCs+Buffer was 1.4-fold higher than the adhesion of non-
PEGylated PLGA spheres in RBCs+Buffer.  However, the adhesion of both particles in plasma 
systems (RBCs+Plasma and whole blood) significantly decreased by approximately 60% relative 
to their respective adhesions in RBCs+Buffer.  The adhesion of PEGylated and non-PEGylated 
spheres in whole blood was not significantly different than the adhesion level observed for the 
same particles in RBCs+Plasma.  Fig. 4.2 shows the adhesion of PEGylated spheres with a PEG 
density corresponding to an intermediate-brush conformation (16,000 PEG chains/µm
2
, Table 
4.2) in buffer and whole blood.  There was no significant difference in particle adhesion in buffer 
or blood flow between the non-PEGylated and PEGylated PLGA spheres.  The adhesion of both 
particles in blood was 85% lower than their respective adhesion densities in buffer flow.  
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Figure 4.1.  Adhesion of non-PEGylated and 5.5 kDa PEGylated (3,785 ± 361 PEG 
chains/µm
2
, mushroom conformation) sLe
a
-targeted (~400 sites/µm
2
) PLGA spheres (3.4 ± 
1.2 µm) in laminar flow at 200 s
-1
 WSR.  * indicates significant difference compared to the 
adhesion of non-PEGylated spheres in the same flow system (p<0.01). # indicates significant 
difference compared to the adhesion of the same particle type in RBCs+Buffer (p<0.01). 
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Figure 4.2.  Adhesion of non-PEGylated and 5.5 kDa PEGylated (16,092 ± 1,247 PEG 
chains/µm
2
, intermediate-brush conformation) sLe
a
-targeted (~1,700 sites/µm
2
) PLGA 
spheres (3.0 ± 1.0 µm) in laminar flow at 200 s
-1
 WSR.  # indicates significant difference 
compared to the adhesion of the same particle in buffer flow (p<0.01). 
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To examine if a higher molecular weight PEG spacer would improve PLGA adhesion in 
blood, 10 kDa PEG spacers were conjugated to the surface of PLGA sLe
a
-targeted spheres with 
enough density to achieve a similar intermediate brush conformation as the 5.5 kDa PEGylated 
PLGA spheres used in Fig. 4.2 (Table 4.3) and their adhesion was assessed in buffer and plasma 
systems at 200 s
-1
 WSR.  Similar to what was observed in Figs. 4.1 and 4.2, there was no 
significant difference in adhesion between non-PEGylated and the 10 kDa PEGylated (3,222 
PEG chains/µm
2
) PLGA spheres in buffer flow and RBCs+Buffer.  In RBCs+Plasma and whole 
blood, the adhesion of the 10 kDa PEGylated was ~ 3- and 2-fold greater than non-PEGylated 
PLGA spheres, respectfully.  The adhesion level of PEGylated spheres in RBCs+Plasma was not 
significantly different than that of the same spheres in RBCs+Buffer; however, the adhesion of 
the PEGylated spheres in whole blood decreased by 60% relative to RBCs+Buffer.  The 
adhesion of non-PEGylated PLGA spheres in RBCs+Plasma and whole blood was ~ 68% lower 
than that of the same spheres in RBCs+Buffer.  
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Figure 4.3.  Adhesion of non-PEGylated and 10 kDa PEGylated (3,222 ± 183 PEG 
chains/µm
2
, intermediate-brush conformation) sLe
a
-targeted (~170 sites/µm
2
) PLGA spheres 
(2.9 ± 0.2 µm) in laminar flow at 200 s
-1
 WSR.  * indicates significant difference compared 
to the adhesion of non-PEGylated spheres in the same flow system (p<0.01). # indicates 
significant difference compared to the adhesion of the same particle type in RBCs+Buffer 
(p<0.01). 
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4.2.2.  Adhesion of PEGylated Polystyrene Microspheres in Pig Blood 
 To investigate whether PEG can improve the adhesion of model VTC in pig blood, 2 µm 
polystyrene microspheres were conjugated with 5.5 kDa and 10 kDa PEG with PEG densities 
corresponding to an intermediate-brush conformation (Table 4.4).  Fig. 4.4 shows the adhesion 
of non-PEGylated and PEGylated polystyrene spheres (sLe
a
-targeted, ~1,000 sites/µm
2
) in 
pRBCs+Buffer, pRBCs+Plasma, and whole blood (pRBC – pig red blood cells) under 200 s-1 of 
laminar flow.  There was no significant difference in particle adhesion between non-PEGylated 
and both PEGylated microspheres (5.5 and 10 kDa) in pRBCs+Buffer.  The adhesion density for 
all particles significantly decreased in pRBCs+Plasma and pig whole blood relative to 
pRBCs+Buffer, resulting in 90%, 86%, and 82% reductions in adhesion for non-PEGylated, 5.5 
kDa PEG, and 10 kDa PEG; respectfully.  There was no significant difference in adhesion 
between the PEGylated and non-PEGylated spheres in pRBCs+Plasma and pig whole blood. 
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Table 4.4.  PEG surface densities and conformations of 2 µm polystyrene 
spheres (PS) used in polystyrene-pig blood flow assays (Fig. 4.4.). 
 
 
 
 
 
 
 
 
Figure 4.4.  Adhesion of non-PEGylated, 5.5 kDa-PEGylated, and 10 kDa –PEGylated 
polystyrene spheres (2 µm) targeted with sLe
a
 (~1,000 sLe
a
 sites/µm
2
) in laminar flow at 200 
s
-1
 WSR.  * indicates significant difference compared to the adhesion of the same spheres in 
pRBCs+Buffer (p<0.01).  
 
 
 
 
 PS-5.5 kDa PEG PS-10 kDa PEG 
PEG Density 11,960 ± 1,624 4,987 ± 40 
PEG Conformation  Intermediate-Brush Intermediate-Brush 
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To determine if increasing the PEG density would restore the adhesion of polystyrene 
microspheres in pig blood to the adhesion level observed in pig plasma-free systems, 2 µm 
polystyrene spheres were conjugated with a 5.5 kDa PEG spacer at 35,367 ± 1,450 PEG 
chains/µm
2
.  The increase in PEG density (relative to the PEG density used in Fig. 4.4) was 
achieved by adjusting the PEG conjugation protocol such that the covalent attachment of PEG 
occurred under conditions with marginal solvation (higher salt concentration and PEG solution 
and increase temperature during conjugation).[13]  The marginal solvation conditions allowed 
for reduced chain repulsion resulting in greater PEG packing at the particle surface.[13]  
Although an increase in PEG density was achieved, the maximum sLe
a
 density conjugated onto 
the PEGylated spheres resulted was only 318 ± 51 sites/µm
2
.  Thus, both the PEGylated and non-
PEGylated spheres used in Fig. 4.5 were conjugated with only 318 ± 51 sLe
a
 sites/µm
2 
instead of 
the 1,000 sLe
a
 sites/µm
2
 used in Fig. 4.4.  There was no significant difference in particle 
adhesion between the non-PEGylated and the high density PEGylated spheres in pRBCs+Buffer 
or pRBCs+Viscous Buffer in which the viscosity of the reconstituting buffer was matched to that 
of pig plasma.  For the non-PEGylated spheres there was a 95% reduction in the adhesion in 
plasma systems (pRBCs+Plasma and pig whole blood) relative to their adhesion in 
pRBCs+Buffer.  However, there was no significant difference in adhesion of the high density 
PEGylated spheres between all pig blood systems examined, and the adhesion of PEGylated 
spheres was approximately 15- and 10-fold greater than non-PEGylated spheres in 
pRBCs+Plasma and pig whole blood, respectfully.  However, preliminary results suggest that the 
negatively impacting plasma proteins are present after long-term exposure to pig plasma (~1 
hour), which suggests that this high density PEGylation (~35,000 PEG chains/µm
2
) may only 
provide short-term improvements to model VTC adhesion in pig blood (data not shown). 
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Figure 4.5.  Adhesion of non-PEGylated and 5.5 kDa-PEGylated (35,367 ± 1,450 PEG 
chains/µm
2
) polystyrene spheres targeted with sLe
a
 (318 ± 51 sLe
a
 sites/µm
2
) in laminar flow 
at 200 s
-1
 WSR.  * indicates significant difference compared to the adhesion of non-
PEGylated spheres in the same flow system (p<0.01).  
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4.3.  Discussion 
The recently identified material dependent plasma effect on the adhesion of DDSs in 
human and animal blood has provided a significant challenge in optimizing vascular targeting.  
While model DDSs, such as polystyrene spheres, allow for easy manipulation of particle 
geometry (size and shape) for optimizing margination and adhesion in blood, their adhesive 
trends cannot be assumed to directly transfer to actual DDSs, such as PLGA spheres, due to 
human and animal plasma exhibiting minimal or no effect on polystyrene VTC adhesion.  
Minimizing or reducing plasma adsorption through PEGylation is a viable option for neutralizing 
the material dependent plasma effect and restoring the adhesion of plasma-sensitive VTCs, such 
as a PLGA DDSs, in blood.  In this chapter, I examine if the addition of PEG onto a PLGA 
microsphere’s surface improves or restores the adhesion of PLGA targeted spheres in blood to 
the adhesion level of PLGA spheres in plasma-free flow systems (buffer only or RBCs+Buffer 
systems).  
While it is often suggested that a PEG brush orientation is required to prevent sufficient 
plasma protein adsorption resulting in increases systemic circulation time (in vivo), there have 
been some reports that show improved circulation time and reduced BSA adsorption with a 
mushroom conformation.[11, 12]  For low density PEGylated PLGA spheres corresponding to a 
mushroom conformation, PEG was unable to improve the adhesion of PEGylated PLGA spheres 
to the adhesion levels observed in RBCs+Buffer (Fig. 4.1).  Interestingly, the adhesion of 
mushroom oriented PEG was significantly higher than non-PEGylated spheres in RBCs+Buffer.  
In Chapter 3, I show that polystyrene-PEG particles in a mushroom conformation significantly 
improved the adhesion of aICAM-1 targeted spheres under unfavorable adhesion conditions (500 
s
-1
 WSR, Fig. 3.4).  I anticipate a similar effect in that the improved adhesion level of PEGylated 
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PLGA spheres with a mushroom conformation in RBCs+Buffer is due to PEG improving the 
adhesive dynamics of the targeting system.[14]  This effect was not observed with polystyrene 
spheres with 1,000 sLe
a
 sites/µm
2
 in Chapter 3, most likely because the higher ligand density 
already being sufficient for adhesion at the WSRs explored.  However, the reduction in adhesion 
of the mushroom PEGylated PLGA spheres in plasma systems suggests that the improvement in 
adhesive dynamics with the addition of PEG in the mushroom conformation are negated in the 
presence of plasma, possibly due to the low PEG density still allowing for sufficient plasma 
protein adsorption.  Thus, I hypothesize that a higher PEG density is required to restore PLGA 
adhesion in human blood.  
 The maximum PEG density (5.5 kDa) obtained on PLGA microspheres was ~ 16,000 
PEG chains/µm
2
 and
 
corresponding to an intermediate-brush conformation (based on the 
relationship between the distance between adjacent PEG chains and Rf (as described in Fig. 2.3).  
Surprisingly, this PEG condition did not significantly improve the adhesion of targeted PLGA 
spheres in plasma systems, relative to non-PEGylated spheres of the same ligand density in 
whole blood (Fig. 4.2).  In fact the adhesion level of PEGylated spheres with 16,000 PEG 
chains/µm
2
 was significantly lower than that observed with the low density PEGylated spheres 
oriented in a mushroom conformation (~3,800 PEG chains/µm
2
), even though the high density 
PEGylated spheres had 4 times as much sLe
a
 density.  The negative plasma effect on PLGA 
adhesion in human blood has been shown to be donor specific; that is, the magnitude of the 
reduction in PLGA adhesion relative to plasma-free systems is dependent on the unique 
concentration of specific plasma proteins (~ 150 kDa molecular weight) in blood.[4]  Thus, it is 
plausible that the lower adhesion level of the high PEG density PLGA spheres in blood (Fig. 
4.2), relative to the mushroom oriented PEG spheres (Fig. 4.1), may be due to the specific donors 
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used for the assay and not related to the PEG density.  The lack of a significant difference in the 
adhesion density between PEGylated and non-PEGylated PLGA spheres in buffer-only suggests 
that PEG in the intermediate-brush conformation did not contribute to the reduction in particle 
adhesion observed with human whole blood (Fig. 4.2).  Previous work using a 5.0 kDa PEG 
reported that a dense brush conformation, where the distance between adjacent PEG chains is < 3 
nm, was necessary for reducing plasma protein adsorption onto nanoparticles.[10, 11, 15]  The 
distance between adjacent PEG chains for the 5.5 kDa PEG chain with ~16,000 PEG chains/µm
2
 
is estimated to be 8.9 nm (estimated using Equation 2.2 from Chapter 2), suggesting that there is 
still sufficient space between adjacent PEG chains for plasma adsorption onto the PEGylated 
DDS; and hence, a negative plasma effect on adhesion. 
To determine if a larger PEG spacer would improve the adhesion of PLGA spheres in 
plasma systems, a 10 kDa PEG was conjugated to PLGA spheres such that the PEG corona was 
oriented in an intermediate-brush conformation (Table 4.3).  I anticipated that the larger PEG 
spacer, relative to the 5.5 kDa PEG, would provide more steric hindrance for blocking plasma 
protein adsorption and potentially restore PLGA particle adhesion in human blood.  The addition 
of a 10 kDa PEG in an intermediate-brush conformation did improve the adhesion of targeted 
PLGA spheres compared to non-PEGylated PLGA spheres in plasma systems (RBCs+Plasma 
and whole blood, Fig. 4.3).  However, the adhesion of 10 kDa PEGylated spheres in whole blood 
was significantly different than the adhesion of the same spheres in RBCs+Buffer and 
RBCs+Plasma.  It remains unclear whether the improved adhesion, relative to non-PEGylated 
spheres, in plasma systems is due to PEG reducing plasma adsorption or simply improving the 
adhesion dynamics of the targeting ligand.  The distance between adjacent PEG chains for the 10 
kDa PEG is estimated to be 19.9 nm which is significantly larger than the estimated distance 
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between adjacent 5.5 kDa PEG chains with ~16,000 PEG chains/µm
2
 (8.9 nm).  Similar to the 
5.5 kDa PEG with ~16,000 PEG chains/µm
2
, it was anticipated that there was still significant 
plasma protein adsorption with the 10 kDa PEG spacer.  Previous work has also shown that the 
stress on an adhesive bond in shear flow decreases with increase PEG molecular weight.[14]  I 
hypothesize that the improvement in PLGA adhesion in RBCs+Plasma with the 10 kDa PEG in 
the intermediate-brush conformation, relative to the adhesion of non-PEGylated spheres, is 
mostly due to improved adhesive dynamics of the targeting ligand and not a reduction in plasma 
protein adsorption.  However in whole blood, the hypothesized improved adhesive dynamics 
with the addition of a 10 kDa spacers is not sufficient to overcome the combined effects of 
plasma adsorption and collisions with rolling leukocytes on the endothelium, resulting in a 
decrease in particle adhesion relative to RBCs+Plasma only (Fig. 4.5).[6] 
The results from this work suggest that higher PEG grafted densities than those used in 
this work (>16,000 and 3,220 PEG chains/µm
2
 for 5.5 and 10 kDa PEG, respectfully) are 
required to reduce the adsorption of negatively impacting plasma proteins on PLGA spheres and 
improve their adhesion in blood.  However, further attempts in increasing the PEG density onto 
PLGA spheres were not successful.  One of the limitations in PEGylating PLGA spheres is the 
low concentration of carboxyl groups available for PEGylation.  This is likely due to low mole 
fraction of carboxyl groups compared to the number of monomers in the polymer, i.e. the only 
carboxylic acid group available for conjugation is present at the end chain of the PLGA polymer.  
I hypothesize that the low density of carboxyl groups available for PEGylation on PLGA spheres 
is the contributing factor in the unsuccessful attempts in achieving higher PEG densities for the 
5.5 and 10 kDa PEG spacers used in this work.  A modified protocol applied to polystyrene 
spheres to increase the PEG density from ~11,000 PEG chains/µm
2
 to ~35,000 PEG (Table 4.4) 
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chains/µm
2
 may not be suitable for PLGA spheres due PLGA microsphere experiencing 
enhanced degradation and plasticization at high temperature, such as that used during high 
density PEG conjugation (60ºC).[16]  As a result, new conjugation or PLGA fabrication 
techniques may be required in order to conjugate higher PEG densities than those achieved in  
this work.  
Polystyrene spheres are often used as model DDSs when optimizing carrier geometry for 
margination and adhesion in blood because they are readily available in a variety of uniform 
sizes and can be easily charged with a high density of carboxyl groups.  Recently it was shown 
that the adsorption of pig plasma onto a targeted polystyrene microsphere significantly reduced 
the adhesion of sLe
a
-targeted spheres in blood flow in a similar manner as the plasma effect of 
human plasma on PLGA targeted spheres (Namdee et al. In preparation. 2015).  Pig in vivo 
models are of particular interest in evaluating VTCs for cardiovascular diseases such as 
atherosclerosis and deep vein thrombosis, because of the similarities in blood coagulation and 
plaque development as human blood.[7, 8]  Similar to what was observed with PEGylated PLGA 
spheres in human blood, the addition of 5.5 kDa (~16,000 PEG chains/µm
2
) or 10 kDa (~5,000 
PEG chains/µm
2
), both in an intermediate-brush conformation, did not restore the adhesion of 
sLe
a
-targeted spheres in the pig plasma systems (pig whole blood or pig RBCs in pig plasma) 
compared to pRBCs+Buffer (Fig. 4.4).  However, increasing the PEG density of 5.5 kDa PEG to 
~35,000 PEG chains/µm
2
 did significantly improve the adhesion of sLe
a
-targeted spheres in both 
pig plasma systems (Fig. 4.5).  In fact, the adhesion of the high PEG density polystyrene spheres 
was similar to the adhesion level observed for polystyrene spheres (~1,000 sLe
a
 sites/µm
2
) at the 
same WSR in human blood (~100 particles/mm
2
, Fig. 3.1).  Interestingly, the distance between 
adjacent PEG chains for the 35,000 PEG chains/µm
2
 polystyrene spheres (5.5 kDa) is estimated 
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to be approximately 6 nm, which suggests there is still sufficient room for plasma protein 
adsorption onto the particle’s surface.  Previous work has shown the 5 kDa PEG chains with a 
distance between PEG chains >3 nm did not show the ability to prevent plasma protein 
adsorption.[11]  While it is possible that the high density PEGylated spheres with ~35,000 PEG 
chains/µm
2
 may not be completely prevent plasma adsorption, it may briefly provide enough 
steric hindrance to reduce the amount of the negatively impacting plasma proteins, which were 
previously identified to be relatively large in size (150 kDa molecular weight), in order to 
establish adhesion to the activated endothelium.  Thus, the adhesion of polystyrene spheres in pig 
blood may be restored by limiting, but not completely preventing, plasma protein adsorption.  
However, it remains unclear if this PEG density (~35,000 PEG chains/µm
2
) improves 
polystyrene adhesion in pig blood beyond the 5 minutes of exposure to plasma as was the case 
with the flow assays used in this work.   
Overall in this chapter, PEGylation was used in an attempt to restore the adhesion of 
sLe
a-
targeted spheres which showed reduced adhesion in plasma systems (PLGA/human blood or 
polystyrene/pig blood).  This study shows that for polystyrene spheres in pig blood, a PEG 
density of ~35,000 PEG chains/µm
2
 is sufficient to restore adhesion of sLe
a
-targeted spheres in 
pRBCs+Plasma and pig whole blood to the adhesion level observed in pRBCs+Buffer.  
However, it is yet to be seen whether improving PLGA adhesion in human blood requires the 
same PEG density (~35,000 PEG chains/µm
2
) that improved polystyrene adhesion in pig blood 
or if PLGA adhesion in human blood may be improved with lower PEG grafting densities.      
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CHAPTER 5  
  
VASCULAR TARGETED CARRIERS AS A PHYSICAL MECHANISM FOR 
BLOCKING LEUKOCYTE RECRUITMENT IN INFLAMMATION 
 
Data from this chapter is being prepared for manuscript submission. 
 
 
5.1.  Introduction 
During inflammation, activated endothelial cells upregulate cell adhesion molecules such 
as E-selectin, P-selectin, ICAM-1, and VCAM-1 that facilitate the leukocyte adhesion cascade 
(LAC) where leukocytes are first captured to the endothelium before firmly adhering and 
eventually trans-migrating into tissue space.[1, 2]  While leukocyte recruitment is crucial for 
pathogen clearance, non-regulated or over-recruitment can result in or significantly affect the 
pathogenesis of several serious diseases.  For example, atherosclerotic plaque development is 
enhanced by the continuous recruitment of leukocytes due to chronic inflammation in 
atheroprone areas, such as in medium to large arteries which experience oscillations or disturbed 
blood flow.[3, 4]   In sepsis, high concentrations of circulating cytokines in blood plasma can 
induce systemic activation, leading to possible organ failure associated with the accumulation of 
neutrophils (the largest subclass of leukocytes) the lungs, liver, and kidneys.[5-8]  In 
ischemia/reperfusion injury, hypoxia induced inflammation recruits neutrophils that release 
reactive oxygen species and proteases, which in turn increase endothelial permeability resulting 
in severe endothelial dysfunction.[9]  
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Influencing leukocyte recruitment has been proposed as a therapy for diseases with 
enhanced pathogenesis due to leukocyte accumulation.  For example, in sepsis, reduced 
leukocyte organ accumulation has been associated with improved survival rates of mice 
subjected to lethal polymicrobial sepsis.[10, 11]  Several strategies using antibodies towards 
CAMs such as E-selectin have shown limited success in improving recovery from 
ischemia/reperfusion injury due to short antibody half-life and development of antibody-antigen 
complexes.[12-14]  VTCs are therapeutic systems designed to circulate the vasculature and 
target the endothelium of diseased tissue via specific molecular recognition.  Inflammatory 
molecules that participate in the LAC, such as E-selectin and ICAM-1, have been proposed as  
targeted molecules for VTC applications in inflammation-associated diseases including various 
cancers and cardiovascular disease.[15, 16]  The potential benefit of VTCs is in providing site-
specific targeting and long term therapeutic delivery, which may alleviate issues with systemic 
clearance associated with anti-adhesion therapies.  However, my knowledge, no systematic study 
exists on the influence of VTC margination on leukocyte adhesion to the vascular wall in a 
physiological blood flow environment.  
During blood flow, red blood cells (RBCs) align in the center of flow resulting in a RBC-
free layer, or cell free layer (CFL), along the endothelium.[17, 18]  Margination is the 
preferential redistribution of cellular/particulate entities towards the endothelial wall and away 
from the RBC core.[18]  Blood leukocytes and platelets are known to actively marginate to the 
CFL through a combination of low wall-induced lift forces, due to their rigidity, and 
heterogeneous collisions with RBCs that send them towards the endothelium.[17, 18]  For VTCs 
to be fully effective, they too must efficiently marginate to the cell-free layer before interacting 
with the endothelium.  Design parameters such as carrier size and targeting moieties have 
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typically been probed for optimizing the functionality of VTCs, including enhancing their 
margination.  However, most VTC optimization has been done with simplified blood such as 
RBCs only in plasma or buffer which eliminates any opportunity for understanding the effect or 
impact of marginating leukocytes on VTC functionality and vice versa.[19-21]  Previously, 
leukocytes were shown to significantly decrease the adhesion of microspheres larger than 2 μm, 
which was attributed to rolling leukocytes colliding with and removing surface-bound particles 
from the endothelium.[22]  However, it currently remains unclear what effect, if any, the VTCs 
have on the interactions of leukocytes with the same vascular area, particularly when competing 
for binding to the same endothelial expressed molecules.     
In this chapter, I investigate whether inflammation-targeting particles can alter leukocyte 
adhesion to an activated endothelial monolayer under physiological blood flow conditions.  
Specifically, targeted polystyrene spheres with diameters ranging from 200 nm - 5 µm were 
perfused in human blood at various concentrations and the adhesion of leukocytes and particles 
was assessed in oscillating flow and laminar flow.  The results demonstrate that VTCs 
significantly influence leukocyte adhesion to the same targeted endothelium in blood flow and 
that the magnitude of the effect is dependent on VTC design parameters such as size and 
targeting moiety, along with particle endothelial surface coverage and hemodynamics. 
 
5.2.  Results 
 The experimental set up used in this chapter is described in detail in Chapter 2. 
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5.2.1.  Influence of sLe
a
-Targeted Spheres and Particle Size on Leukocyte Adhesion 
Figure 5.1 (A-E) shows the effect of sLe
a
-targeted spheres on leukocyte adhesion to an 
activated endothelium in oscillating human blood flow as a function of particle size and 
concentration.  Leukocyte adhesion with the presence of particles in blood was normalized to the 
leukocyte adhesion density observed with particle-free blood of the same blood donor as 
described is Chapter 2, i.e. a value of 1 indicates the leukocyte adheison density with the 
presence of VTCs was equivalent to the leukocyte adhesion density in particle-free blood.  The 
presence of the 5 µm targeted spheres at a concentration of 5x10
5
 particles/mL in blood flow 
resulted in a 22% decrease in leukocyte adhesion relative to particle free blood (Fig. 5.1.A).  
Increasing the concentraiton of 5 µm targeted spheres to 1x10
6 
and 2.5x10
6
 particles/mL in blood 
further decreased leukocyte adhesion 54% and 74%, respectfully.  A blood concentration of the 5 
µm sLe
a
-spheres at 1x10
7
 particles/mL decreased leukocyte adhesion by 97% relative to particle-
free blood.  Unlike the 5 µm targeted spheres, 3 µm targeted spheres at 5x10
5
 particles/mL did 
not affect leukocyte adhesion in flow (Fig. 5.1.B).  When the blood concentration of the 3 µm 
targeted spheres was increased to 1x10
6
 and 2.5x10
6
 particles/mL, leukocyte adhesion decreased 
by 40% and 35%, respectively, relative to particle-free blood.  There was, however, no 
significant difference in the normalized leukcotye adhesion level between 1x10
6
 or 2.5x10
6
 
particles/mL.  Further increasing the concentraiton of 3 µm targeted spheres to 1x10
7
 
particles/mL reduced leukocyte adhesion by 98%.  For 2 µm spheres (Fig. 5.1.C), there was no 
significant effect on leukocyte adhesion compared to particle-free blood with blood 
concentrations of  5x10
5
 and 1x10
6
 particles/mL.  At concentrations of 2.5x10
6
 and 1x10
7
 
particles/mL, 2 µm spheres significantly decreased leukocyte adhesion by 27% and 69%, 
respectively.   
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500 nm spheres (Fig. 5.1.D) in 5x10
5
 and 1x10
6
 particles/mL blood concentrations, did 
not significantly affect leukocyte adhesion.  Increasing the concentration of the 500 nm targeted 
spheres in blood to 2.5x10
6  
and 1x10
7
 particles/mL significantly decreased leukocyte adhesion 
by 22% and 39%, respectfully.  Fig. 5.1.E shows the effect of 200 nm targeted spheres on 
leukocyte adhesion.  At 1x10
7
 particles/mL there was no significant effect on leukocyte 
adhesion.  Interestingly, when increasing the concentration of 200 nm targeted spheres such that 
their volume concentration in blood (1.8x10
8
 particles/mL) was similar to the volume of 500 nm 
spheres at 1x10
7
 particles/mL, the 200 nm targeted spheres significantly decreased leukocyte 
adhesion by 40%, a value similar to the reduction observed with 500 nm targeted spheres (1x10
7
 
particles/mL, Fig. 5.1.D).  
The particle adhesion densities corresponding to the particles used in Fig. 5.1. (A-E) are 
shown in Fig. 5.2 (A-E).  For 5 µm, 3 µm, 2 µm, and 500 nm targeted spheres, there was no 
significant difference in particle adhesion between blood with 5x10
5
 anad 1x10
6
 particles/mL 
(Fig. 5.2.A-D).  There was also no signifciant diference between the particle adhesion of 5 µm 
targeted spheres with 1x10
6
 and 2.5x10
6
 particles/mL.  For all particle sizes, the adhesion density 
increased when increasing the particle blood concentraton from 2.5x10
6
 to 1x10
7
 particles/mL.  
Overall, the particle adhesion densites for the various sizes followed previously reported trends 
such that at a fixed blood concentraion the particle adhesion density of 2 and 3 µm  > 5 µm > 
500 nm > 200 nm spheres.[20, 23]   
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Figure 5.1.  Normalized leukocyte adhesion with the presence of (A) 5 µm, (B) 3 µm, (C) 2 
µm, and (D) 500 nm, (E) 200 nm sLe
a
-targeted spheres (~1,000 sites/µm
2
) at various blood 
concentrations under oscillating flow. * indicates significant difference in leukocyte adhesion 
relative to particle-free blood (p<0.01). 
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Figure 5.2.  Particle adhesion densities for (A) 5 µm, (B) 3 µm, (C) 2 µm, and (D) 500 nm, 
(E) 200 nm targeted spheres (~1,000 sLe
a
 sites/µm
2
) at various blood concentrations in 
oscillating flow. * indicates significant difference in particle adhesion relative to adhesion 
density with 5x10
5
 particles/mL of the same particle size (p<0.01). 
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To determine if the impact of targeted particles on leukocyte adhesion was due to 
molecular interactions of particles with the targeted molecule or just by their physical presence in 
flow, I explored the adhesion of leukocytes in blood flow containing non-targeted particles in the 
various size range explored in Fig. 5.1.  Non-targeted 5 µm spheres with blood concentraitons of 
1x10
6
, 2.5x10
6
, and 1x10
7
 particles/mL signifcanly reduced leukocyte adhesion by 28%, 53%, 
and 88%, respectfully, relative to particel free blood (Fig. 5.3.A).  There was no significant effect 
of the 5 µm non-targeted spheres at 5x10
5
 particles/mL.  For  3 µm 5x10
5
 particles/mL 
concentration significantly decreased leukocyte adhesion relative to particle-free blood; however, 
there was no significant effect on leukocyte adhesion with of any other particle concentrations 
explored for this particle size (Fig. 5.3.B).  No reduction in leukcoyte adhesion was observed 
with any of the particle concentrations explored for 2 µm, 500 nm, and 200 nm non-targeted 
spheres (Fig. 5.3 D, C, and E).  
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Figure 5.3.  Normalized leukocyte adhesion with non-targeted (A) 5 µm, (B) 3 µm, (C) 2 
µm, and (D) 500 nm, (E) 200 nm spheres at various blood concentrations. * indicates 
significant difference in leukocyte adhesion relative to particle-free blood (p<0.01). 
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To elucidate whether competion for adhesion to the endothelium between targeted 
particles and leukocytes resulted in the reduced leukocyte adhesion shown in Fig. 5.1, I plotted 
the percent reduction in leukocyte adhesion relative to particle-free blood, along with the 
corresponding adhesion densities for the sLe
a
-targeted particles at 2.5x10
6 
(Fig. 5.4.A) and 1x10
7
 
(Fig. 5.4.B) particles/mL concentrations.  The maximum reduction in leukocyte adhesion with 
2.5x10
6
 particles/mL (75% leuckoyte reduction) was observed when targeted 5 µm spheres were 
present in blood flow, even though the particle adhesion density for the spheres was 
aproximately 4-fold less than the particle adhesion of 3 µm and 2 µm spheres (Fig. 5.4.A).  
There was no significant difference in particle adhesion between 5 µm and 500 nm targeted 
spheres; however, 500 nm targeted spheres decreased leuckoyte adhesion by only 22%.  For the 
1x10
7
 particles/mL blood concentration (Fig. 5.4.B), 5 µm and 3 µm spheres decreased 
leukocyte adhesion by 97% and 98%, respectfully, even though the adhesion of 5 µm spheres 
was 2-fold lower than 3 µm spheres.  The adhesion density of 3 µm spheres was not significantly 
different than the adhesion of 2 µm spheres; however, 2 µm spheres reduced the leukocyte 
adhesion by only 69% relative to particle free blood.  Interestingly, while the particle adhesion 
for 2 µm spheres was 4-fold greater than that of 500 nm spheres at the same concentration, the 
percent reduction in leukocyte adhesion with 2 µm spheres was only 1.8-fold greater than that 
observed with 500 nm spheres (39% reduction).  200 nm targeted spheres did not affect 
leukocyte adhesion and its particle adhesion density was significantly lower than all other 
particle sizes with 1x10
7
 particles/mL concentration in blood.   
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Figure 5.4.  Reduction in leukocyte adhesion (black bars. left axis), relative to particle-free 
blood, with the adhesion densities of sLe
a
-targeted spheres (white bars, right axis) at (A) 
2.5x10
6
 particles/mL and (B) 1x10
7
 particles/mL in oscillating blood flow.  For 2.5x10
6
 
particles/mL (A) significance was compared to the reduction in leukocyte adhesion with 5 
µm targeted spheres (*).  For 1x10
7
 particles/mL (B) significance was compared to the 
reduction in leukocyte adhesion with 3 µm targeted spheres (#) and 2 µm targeted spheres 
(##). (p<0.01). 
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The leukocyte adhesion density with the presence of 5 µm or 2 µm non-targeted and 
targetd spheres in blood with 5x10
5
 particles/mL was also examined over the elapsed 
experimental time to determine if the reduction in leukocyte adhesion occured instananeously or 
after particle accumulation at the endothelium.  In gerneral, the leukocyte adhesion in particle-
free blood linearly increased throughout the experiment (Fig. 5.5.A, B - red circles).  The 
leuckocyte adhesion trend with time was not significantly altered with the presence of non-
targeted 5 µm (yellow triangles) or non-targeted 2 µm spheres (yellow diamonds) in blood (Fig. 
5.5.A, B).  The presence of 2 µm targeted spheres (blue diamonds)  had no significant impact on 
the leukocyte adhesive trend.  Interestingly with 5 µm targeted spheres (blue triangles), a 
separation in the leukocyte adhesive trends between particle-free blood and blood with targeted 
spheres ocurred aproximately 3-4 minutes into the elapsed experiment.  After this, the leukocyte 
adhesion plateaued while the adhesion in particle-free blood continued to increase with time 
(Fig. 5.5.A).  At this same time range, the particle adhesion for 5 µm spheres also plateaued 
while adhesion of 2 µm targeted spheres increased linearly with time (Fig. 5.5.C).[22] 
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Figure 5.5.  Leukocyte adhesion density vs. time with the presence of targeted and non-
targeted (A) 5 µm spheres and (B) 2 µm spheres in blood with 5x10
5
 particles/mL in 
oscillating blood flow, along with (C) the corresponding particle adhesion densities for 
targeted spheres (1,000 sLe
a
 sites/µm
2
). 
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5.2.2.  Influence of  Particle Shape on Leukocyte Adhesion in Oscillating Blood Flow 
 The influence of VTC shape on leukocyte adhesion was examined in oscillating blood 
flow using sLe
a
-targeted rods of aspect ratio (AR) 4 and 9 (2 µm equivalent spherical volume).  
Table 5.1 shows the measurements for the major and minor lengths and surface area for AR4 and 
AR9 rod.  There was no significant effect on leukocyte adhesion with the presence of AR4 or 
AR9 rods with 5x10
5
 particle/mL blood concentrations (Fig. 5.6). The particle adhesion for AR4 
rods was not significantly different than the adhesion of 2 µm spheres; however, the adhesion of 
AR9 rods was 4.6-fold lower than the adhesion of 2 µm spheres and AR4 rods under the same 
blood flow conditions (Fig. 5.6).  The presence of the higher aspect ratio rods in blood did not 
affect the leukocyte adhesion profile with time, relative to particle-free blood (Fig. 5.7.A).  
Similar to what was observed with 5 µm sLe
a
-targeted spheres (Fig. 5.5.C), the adhesion of AR9 
rods linearly increased within the first 5 minutes of blood flow, after which the adhesion 
decreased throughout the remainder of the flow assay (Fig. 5.7.B).  
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Table 5.1.  Measurements of aspect ratio (AR), major axis length, 
minor axis length, and surface area of rods used in Fig. 5.6 and 5.7. 
 
 
 
 
 
 
 
 
 
Figure 5.6.  Normalized leukocyte adhesion (black bars, left axis) and particle adhesion 
(white bars, right axis) with the presence of AR4 and AR9 rods in blood with 5x10
5
 
particles/mL.  # indicates significant difference in particle adhesion relative to AR4 rods 
(p<0.01). 
 
 
 
 
 
AR 4 Rods AR 9 Rods 
Aspect Ratio 4.26 ±  1.20 8.89 ± 2.68 
Major Axis Length 6.32 ± 1.11 µm 11.81 ± 2.03 µm 
Minor Axis Length 1.55 ± 0.25 µm 1.31 ± 0.21 µm 
Surface Area 24.38 ± 3.13 µm
2
 35.76 ± 5.15 µm2 
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Figure 5.7.  (A) Leukocyte and (B) particle adhesion densities vs. time in oscillating blood 
flow with sLe
a
-targeted AR9 rods (open triangles) with 2 µm equivalent spherical volume at 
5x10
5
 particles/mL blood concentration. 
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5.2.3.  Influence of sLe
a
-Ligand Density on Leukocyte Adhesion 
 The influence of VTC ligand density was examined to determine if increasing sLe
a
 
density would affect leukocyte adhesion through enhanced molecular interactions between L-
selectin present on leukocytes and sLe
a
-targeted spheres (as sLe
a
 interacts with L-selectin 
expressed on leukocytes).  The leukocyte adhesion was examined with 2 µm or 5 µm spheres 
with either 600 or 2,100 sLe
a
 sites/µm
2
 in oscillating blood flow with a blood concentration of 
5x10
5
 particles/mL.  There was no significant effect of 2 µm targeted spheres with either 600 or 
2,100 sLe
a
 sites/µm
2
 on leukocyte adhesion, relative to particle-free blood (Fig. 5.8.A).  The 
particle adhesion of 2 µm spheres with 600 and 2,100 sLe
a
 sites/µm
2
 was not significantly 
different than the adhesion of 2 µm spheres with 1,000 sLe
a
 sites/µm
2
 at the same blood 
concentration (5x10
5
 particles/mL, Fig. 5.2.C).  5 µm targeted spheres with 2,100 sLe
a
 sites/µm
2
 
decreased leukocyte adhesion by 18% (Fig. 5.8.B), relative to particle-free blood, and this 
decrease was not significantly different compared to the percent reduction in leukocyte adhesion 
observed with 1,000 sLe
a
 sites/µm
2
 at the same blood concentration (5x10
5
 particles/mL, Fig. 
5.1.A).  The particle adhesion for 5 µm spheres with 2,100 sLe
a 
sites/µm
2
 was also not 
significantly different then the adhesion of 5 µm spheres with 1,000 sLe
a 
sites. 
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Figure 5.8.  Normalized leukocyte (black bars, left axis) and particle adhesion (white bars, 
right axis) with (A) 2 µm and (B) 5 µm sLe
a
 targeted spheres with 600 or 2,100 sLe
a
 
sites/µm
2
.  * indicates significant difference in leukocyte adhesion compared to particle-free 
blood (p<0.01). 
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5.2.4.  Effect of aICAM-1 Targeted Spheres on Leukocyte Adhesion 
To determine whether the observed effect of E-selectin-targeted particles on leukocyte 
adhesion would occur with particles targeted to other inflammatory molecules, I observed the 
impact of aICAM-1 targeted spheres on leukocyte adhesion for 5 µm, 2 µm and 500 nm spheres 
in oscillating blood flow (Fig. 5.9).  5 µm aICAM-1-targeted spheres with 5x10
5
 and 2.5x10
6
 
particles/mL blood concentrations decreased leukocyte adhesion by 26% and 55%, respectfully, 
relative to particle-free blood.  The reductions in leukocyte adhesion with 5 µm aICAM-1 
targeted spheres was not significantly different than what was observed with 5 µm sLe
a
-targeted 
spheres at the same particle concentrations (Fig. 5.1.A).  The particle adhesion for 5 µm aICAM-
1 targeted spheres with 5x10
5
 particles/mL in blood was 3-fold lower than the adhesion of sLe
a
-
targeted spheres of the same size and blood concentration (Fig. 5.2.A).  There was no difference 
in the particle adhesion between sLe
a
-targeted and aICAM-1 targeted 5 µm spheres with 2.5x10
6
 
particles/mL in blood.  Contrary to the 5 µm spheres, 2 µm aICAM-1 targeted spheres at 5x10
5 
and 2.5x10
6 
particles/mL did not significantly decrease leukocyte adhesion compared to particle-
free blood. There was, however, a 61% reduction in leukocyte adhesion with 1x10
7
 particles/mL 
concentration for this particle size (Fig. 5.9.B).  This percent reduction was not significantly 
different from that observed with 2 µm sLe
a
-targeted spheres at the same particle concentration 
(Fig. 5.2.C ).  There was no significant difference in particle adhesion between aICAM-1 and 
sLe
a
-targeted 2 µm spheres with all concentrations explored.  For both 2 µm and 5 µm aICAM-1 
targeted spheres the particle adhesion density significantly increased with increasing VTC 
concentration in blood, relative to that observed with same particle size with 5x10
5 
particles/mL.  
The influence of targeting ligand on leukocyte adhesion was also investigated using 500 nm 
aICAM-1 targeted spheres in blood with 1x10
7
 particles/mL (Fig. 5.9.C).  500 nm aICAM-1 
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targeted spheres significantly decreased leukocyte adhesion, relative to particle-free blood, by 
37% and this reduction was not significantly different from what was observed with 500 nm 
sLe
a
-targeted spheres at the same particle concentration (Fig. 5.1.D).  Interestingly, the particle 
adhesion of 500 nm aICAM-1 targeted spheres was 2.5-fold greater than the adhesion of 500 nm 
sLe
a
-targeted spheres at the same particle concentration (Fig. 5.2.D)  
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Figure 5.9.  Normalized leukocyte adhesion (black bars, left axis) and particle adhesion 
(white bars, right axis) of (A) 5 µm, (B) 2 µm, and (C) 500 nm aICAM-1 targeted spheres 
(~6,000 sites/µm
2
) under oscillating blood flow.  * indicates significant difference in 
leukocyte adhesion relative to particle-free blood.  # indicates significant difference in 
particle adhesion compared to the adhesion of the same particle size at 5x10
5
 particles/mL 
(p<0.01). 
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5.2.5.  Influence of VTCs on Leukocyte Adhesion in Laminar Flow 
To investigate if the influence of VTCs on leukocyte adhesion would be limited to 
oscillating blood flow, the effect of 5 µm, 2 µm, and 500 nm sLe
a
-targeted spheres on leukocyte 
adhesion was examined under laminar blood flow conditions with 200 and 1,000 s
-1
 WSR.  
There was no significant effect on leukocyte adhesion with 5 µm targeted spheres at 200 s
-1 
(5x10
5 
particles/mL, Fig. 5.10.A).  With 1,000 s
-1
 WSR, 5 µm targeted spheres significantly 
decreased leukocyte adhesion by 45% even though there was no significant difference in particle 
adhesion between 200 and 1,000 s
-1
 WSRs.  The presence of 2 µm or 500 nm sLe
a
-targeted 
spheres in blood with 1x10
7
 particles/mL did not significantly affect leukocyte adhesion with 
200 s
-1
 WSR of laminar blood flow (Fig. 5.10.A, B).  When increasing the WSR to 1,000 s
-1
, 2 
µm and 500 nm targeted spheres significantly reduced the leukocyte adhesion by 71% and 33%, 
respectfully.  The particle adhesion for 2 µm and 500 nm targeted spheres under 1,000 s
-1
 
laminar flow increased by 3-fold and 10-fold, respectfully, relative to the particle adhesion of the 
same spheres with 200 s
-1
 of laminar flow.  There was no effect on leukocyte adhesion with 5 
µm, 2 µm, or 500 nm non-targeted spheres at the WSRs explored for laminar blood flow (Fig. 
5.11) 
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Figure 5.10.  Normalized leukocyte adhesion in laminar blood flow with (A) 5 µm, (B) 2 
µm, and (C) 500 nm sLe
a
-targeted spheres with blood concentrations of 5x10
5
, 1x10
7
, and 
1x10
7
 particles/mL, respectfully, as a function of WSR.  * indicates significant difference in 
adhesion relative to particle-free blood at the same wall shear rate.  # indicates significant 
difference compared to the particle adhesion of the same spheres at 1,000 s
-1 
WSR (p<0.01).  
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Figure 5.11.  Normalized leukocyte in laminar blood flow adhesion with non-targeted (A) 5 
µm, (B) 2 µm, and (C) 500 nm spheres at blood concentrations of 5x10
5
, 1x10
7
, and 1x10
7
 
particles/mL, respectfully, as a function of WSR.   
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5.3.  Discussion 
 Vascular targeting is a viable strategy for the therapeutic intervention of many 
inflammatory diseases, including atherosclerosis and other cardiovascular diseases, aimed 
towards tissue specific drug delivery that results in enhanced drug efficacy and minimized 
systemic side effects.  The redistribution of leukocytes, platelets, and inflammation targeting 
drug carriers to the cell-free layer during blood flow may generate competition for the targeted 
receptors such as E-selectin and ICAM-1, which play pivotal roles in the LAC.  While 
leukocytes were previously shown to decrease levels of particle adhesion, to date, little is known 
as to whether VTCs enhance, diminish, or have no effect on the inflammatory recruitment of 
leukocytes in blood flow to the same targeted tissue.[22]  Understanding the capacity of VTCs to 
positively or negatively impact leukocyte adhesion to the vascular wall would be critical to their 
eventual clinical use for drug delivery in inflammation-associated diseases.  For example in 
atherosclerosis and sepsis, where excessive leukocyte recruit is known to negatively impact 
pathology, a positive impact of VTCs on leukocyte recruitment would likely counteract the effect 
of the delivered therapy.[3, 4]  Conversely, a negative VTC impact on leukocyte recruitment 
(separate from drug action) would likely enhance treatment.  In the case of the latter, the VTCs 
themselves may then be developed as an anti-inflammatory therapy, separate from targeted 
delivery, for effective local treatment of inflammatory diseases. 
Overall, the results of this work show that spherical VTCs targeted towards inflammatory 
molecules either have no impact or significantly reduce the recruitment and adhesion of 
leukocytes to an inflamed endothelium in human blood flow, depending on the particle size and 
concentration in blood.  For most particle sizes explored, the impact of the VTCs on leukocyte 
recruitment requires the molecular targeting of specific EC-expressed inflammatory molecules.  
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No significant reductions in leukocyte adhesion were observed with 5 µm spheres at 5x10
5
 
particles/mL or with smaller non-targeted particles at all the blood concentrations explored.  
Exceptions were found with non-targeted 5 µm spheres at higher blood concentrations of 1x10
6
, 
2.5x10
6
, and 1x10
7
 particles/mL, where significant decreases in leukocyte adhesion occurred 
regardless of targeting (Fig. 5.3A).  However, the addition of targeting ligand (sLe
a
) provided up 
to a 2-fold increase in percent leukocyte reduction, relative to non-targeted 5 µm spheres at the 
same blood concentrations (Figs. 5.1.A, 5.3.A).  The increase in percent leukocyte reduction with 
the addition of targeting ligand (sLe
a
) was dependent on particle concentration in blood, as there 
was nearly a 2-fold increase in percent leukocyte reduction with 1x10
6
 particles/mL for 5 µm 
targeted spheres, relative to non-targeted spheres, but only a 1.1-fold increase with 1x10
7
 
particles/mL.  Particle-leukocyte collisions were previously shown to remove adherent 5 µm 
sLe
a
-targeted spheres from an activated EC monolayer in blood flow under the same oscillating 
flow conditions explored in this work.[22]  I anticipate similar dynamics between leukocytes 
present on the endothelium and 5 µm spheres such that the collision impact from these large 
microspheres weakens the interaction between leukocytes and the endothelium, which under 
high shear conditions, would result in leukocyte detachment from the endothelium.  The 
observed impact with non-targeted 5 µm sphere, but not smaller spheres, suggests that there is a 
minimum impact force and collision frequency required to observe reductions in leukocyte 
adhesion with non-targeted spheres, which is linked to particle size and concentration in blood.   
The maximum reduction in leukocyte adhesion with targeted spheres was observed when 
either 5 µm or 3 µm sLe
a
-targeted spheres were present at the highest blood concentration (1x10
7
 
particles/mL), resulting in nearly 100% prevention of leukocyte binding to the EC monolayer 
(Fig. 5.4.B).  Both particles sizes similarly impacted leukocyte adhesion despite significant 
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differences in their particle adhesion density.  This is likely a result of 5 µm spheres impacting 
leukocyte adhesion through collisions, which was minimal for 3 µm spheres.  As a result, VTCs 
< 5 µm require high particle adhesion densities (i.e. endothelial surface coverage) to achieve 
similar levels of leukocyte reduction relative to 5 µm spheres.  Interestingly, the adhesion of 2 
µm spheres at this same blood concentration (1x10
7
 particles/mL) was not significantly different 
than 3 µm spheres; however, the presence of 2 µm targeted spheres resulted in only a 69% 
reduction in leukocyte adhesion (Fig. 5.4.B).  Here, the fact that smaller 2 µm spheres occupy 
less endothelial surface area, relative to 3 µm spheres, and the absence of physical collisions 
having an impact, likely allows for more endothelial area and receptors available for leukocyte 
adhesion (given similar levels of particle adhesion, Fig. 5.4.B).  Overall, I suspect that for 
smaller micron-sized spheres (2 µm and 3 µm), the endothelial surface coverage, which is 
dependent on the particle size and adhesion density, is the primary factor in reducing leukocyte 
adhesion. For spheres 5 µm or larger, physical collisions with leukocytes at wall are the leading 
factor in decreasing leukocyte adhesion in blood flow. [22] 
Submicron, 500 nm and 200 nm, sLe
a
-targeted spheres were also shown to significantly 
reduce leukocyte adhesion at high blood concentrations, even though the particle adhesion 
densities for nanospheres were significantly lower than that of microspheres at a fixed blood 
concentration (Fig. 5.4).  For example at 2.5x10
6
 particles/mL blood concentration, the reduction 
in leukocyte adhesion with 500 nm was similar to that observed with 3 µm spheres at the same 
blood concentration, despite a 4-fold greater particle adhesion for the 3 µm spheres relative to 
the 500 nm spheres (Fig. 5.4.A).  In fact, the maximum leukocyte reduction with 2 µm targeted 
spheres at the 1x10
7
 particles/mL blood concentration was also only 1.5-fold greater than the 
maximum reduction observed with nanospheres, compared to a 4- and 6-fold higher adhesion for 
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the 2 µm sLe
a
-targeted spheres relative to the adhesion of 500 nm and 200 nm targeted spheres at 
1x10
7
 and 1.8x10
8
 particles/mL, respectfully (Fig. 5.4.B).  The results suggest that the 
mechanism behind nanospheres reducing leukocyte adhesion may be a result of a combined 
effect of particle adhesion at the vessel wall and nanospheres interacting with leukocytes away 
from the endothelium in blood flow.  Recent literature supports this notion that nanoparticle 
interaction with leukocytes can occur in free stream.  In one work, E-selectin-coated nano-sized 
liposomes (~118 nm) were shown to effectively target and adhere to neutrophils in low shear 
blood flow (188 s
-1
).[24]  I suspect that sLe
a
-targeted nanospheres may interact with L-selectin 
expressed on leukocytes possibly through coating the leukocyte or aiding in the formation of 
leukocyte aggregates which would experience increased drag forces, relative to a single 
leukocyte, and reduce the adhesive ability of leukocytes under high shear.  However, it is unclear 
if particle-leukocyte aggregates are stable under high shear conditions due to the fast on-/off- 
rates of L-selectin and sLe
a
 used in this work.[25, 26]  Interestingly, increasing the sLe
a
-density 
on 2 µm and 5 µm spheres (to improve the likelihood of VTC-leukocyte interactions in flow) had 
no significant effect on leukocyte adhesion (Fig. 5.8).  This suggests that the potential for 
particle-leukocyte aggregates through sLe
a
-L-selectin may be limited to nanospheres.  Leukocyte 
aggregates with microspheres in blood flow may require a sLe
a
 density >2,000 sites/µm
2
 or 
implementing leukocyte specific ligands with more favorable adhesive dynamics than that of 
sLe
a
 with L-selectin.   
Ellipsoidal particles (rods) have been proposed for improving VTC adhesion in blood due 
to their enhanced adhesive dynamics in flow.[19, 27]  The influence of AR4 and AR9 rods on 
leukocyte adhesion was examined and shown to have no significant impact on leukocyte 
adhesion, despite the fact that that the area of the endothelium occupied by AR4 rods was 
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approximately 1.8-fold greater than 2 µm spheres with an equivalent volume (due to AR4 rods 
having a greater surface area than equivalent volume spheres) given similar particle adhesion 
densities (Fig. 5.6.A).  This may be a result of a minimum VTC endothelial surface coverage, 
which is dependent on VTC shape and adhesion density, required for influencing leukocyte 
adhesion.  Previous work with AR9 rods in RBCs+Buffer systems under the similar oscillating 
flow conditions showed improve adhesion relative to equivalent volume spheres; however, hear I 
report that the adhesion of AR9 rods in whole blood was significantly lower than 2 µm 
equivalent volume spheres and AR4 rods.[19]  The adhesion vs. time curve shows that the 
adhesion of AR9 ellipsoids plateaued after 5 minutes of oscillating blood flow (Fig. 5.7.B), a 
trend that was similar to that observed with 5 µm spheres (Fig. 5.5.C) where collision with 
leukocytes resulted in decreased particle and leukocyte adhesion with time.  Unlike 5 µm 
spheres, AR9 rods did not significantly influence leukocyte adhesion relative to particle-free 
blood, indicating that a leukocyte collision effect similar to that observed with 5 µm targeted 
spheres at the same blood concentration (5x10
5
 particles/mL) does not occur with AR9 rods in 
blood.   
I also demonstrate that both E-selectin and ICAM-1 targeted particles affect leukocyte 
adhesion in blood flow.  However, there appears to be a difference in the sensitivity of leukocyte 
adhesion to two the different VTC targeting systems, which is also dependent on the particle size 
and adhesion density (Fig. 5.9).  For instance, similar levels of leukocyte reduction were 
observed with both sLe
a 
and aICAM-1 targeted 5 µm spheres, further highlighting physical 
collisions between these large microspheres and leukocytes as the dominant factor in reducing 
leukocyte adhesion.  In contrast, the reduction in leukocyte adhesion induced by 2 µm targeted 
spheres showed sensitivity towards targeting ligand type in that at 2.5x10
6
 particles/mL, sLe
a
-
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targeted spheres resulted in a 27% decrease in leukocyte adhesion whereas no effect on 
leukocyte adhesion was observed with aICAM-1 targeted spheres at the same blood 
concentration.  This may be due to sLe
a
-targeted spheres reducing the amount of E-selectin 
available for initial leukocyte capture from blood flow, which is critical for leukocyte 
recruitment and subsequent adhesion under high shear conditions.[26]  Even though 2 µm 
aICAM-1 targeted spheres would reduce the number of ICAM-1 sites available for leukocyte 
firm adhesion, the smaller particle size (relative to leukocytes which are ~7-12 µm in diameter) 
may allow leukocytes to navigate the endothelial surface through available E-selectin until firm 
adhesion can be established.  However, above a critical particle adhesion density for this VTC 
size, sensitivity towards targeting ligand is lost due to targeted microspheres occupying a critical 
endothelial surface area which minimizes the potential for endothelial-leukocyte interactions 
through either inflammatory receptor (E-selectin or ICAM-1).  The 500 nm aICAM-1 targeted 
spheres with blood concentration of 1x10
7
 particles/mL also significantly reduced leukocyte 
adhesion.  Interestingly, both aICAM-1 and sLe
a
-targeted spheres reduced leukocyte adhesion by 
approximately 40%, despite the adhesion density for aICAM-1 nanospheres being 2.5-fold 
higher than sLe
a
-targeted spheres at the same blood concentration.  To my knowledge, no 
leukocyte receptors exist for the aICAM-1 targeting ligand used in this work, suggesting that 
molecular interactions between aICAM-1 targeted nanospheres and leukocytes are minimal or 
non-existent.  Thus, it is evident that the influence on leukocyte adhesion from the presence of 
nanospheres in blood is not solely dependent on molecular interactions with leukocytes, but a 
component exists in which nanospheres occupying CAMs on the endothelium contributes to 
reducing leukocyte adhesion.  The results also suggest that targeted nanospheres with the 
potential to interact with leukocytes in flow are more effective in reducing leukocyte adhesion, 
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as sLe
a
-targeted nanospheres achieved a similar level of leukocyte reduction as aICAM-1 
targeted nanospheres with lower particle adhesion density at the same particle concentration in 
blood (Fig. 5.9.C, 5.4.B).   
The results also indicate that a hemodynamic component exists with VTCs influencing 
leukocyte adhesion in blood flow.  Significant reductions in leukocyte adhesion were observed 
for 5 µm, 2 µm, and 500 nm sLe
a
-targeted spheres under laminar blood flow at WSR of 1,000 s
-1
, 
but not at 200 s
-1
.  The adhesion of 2 µm spheres under 200 s
-1 
of laminar blood flow (1x10
7
 
particles/mL, Fig. 5.10.B) was also similar to that observed with 2 µm spheres under oscillating 
flow with 2.5x10
6
 particles/mL (~3,400 particles/mm
2
, Fig. 5.4.A), which decreased leukocyte 
adhesion by ~ 20%.  Under high shear conditions (i.e. 1,000 s
-1
 WSR), leukocytes must interact 
with a greater number of CAMs to combat higher drag forces and maintain adhesion with the 
endothelium.  This is of particular importance for initial capture and rolling adhesion during the 
leukocyte recruitment process.  VTCs are more effective in reducing leukocyte adhesion under 
high shear conditions due to adherent particles reducing the number of CAMs available for 
leukocyte capture and adhesion.  Leukocytes also experience slower rolling velocities under low 
shear conditions, which allows them to maintain sufficient contact with the endothelium when 
navigating endothelial-bound VTCs.[28]  Interestingly, 2 µm spheres were more effective in 
influencing leukocyte adhesion under high shear laminar flow compared to oscillating flow, as 
both flow profiles decreased leukocyte adhesion by ~70%.  However, the particle adhesion under 
laminar flow was 2-fold lower than that observed under oscillating blood flow with the same 
blood concentration (1x10
7
 particles/mL, Figs. 5.10.B, 5.4.B).  This may be a function of the 
oscillating flow profile allowing greater contact time between leukocytes and the endothelium, 
due to a zero shear point occurring in the oscillating profile during flow reversal.  As a result, a 
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higher particle adhesion density is required to combat the enhanced contact between leukocytes 
and the endothelium and achieve similar levels of leukocyte reduction relative to high shear 
laminar flow.  The hemodynamic component to VTCs influencing leukocyte adhesion is of 
particular interest for optimizing VTCs as anti-adhesion therapy.  The result suggests that VTCs 
would be effective at reducing leukocyte adhesion under high shear conditions, as is this case in 
medium to large arteries susceptible to cardiovascular disease, while maintaining homeostatic 
leukocyte recruitment in low shear vessels, such as post-capillary venules, where leukocyte 
recruitment and tissue extravasation occurs to combat local infections 
Overall, leukocyte adhesion was shown to be affected by the presence of VTCs in blood.  
The mechanism of reduced leukocyte adhesion with VTCs appears to be dependent on VTC size 
and adhesion density.  The effect on leukocyte adhesion with 5 µm spheres is dependent on 
particle adhesion density and collisions with endothelial-interacting leukocytes.  For 
microspheres 2 -3 µm in diameter, leukocyte adhesion is sensitive to particle adhesion density, 
endothelial surface coverage, and targeting system.  The impact on leukocyte adhesion from 
targeted nanospheres in blood may be due to a combined effect of occupying CAMs on the 
endothelium and interacting with leukocytes away from the vessel wall.  The influence of VTCs 
on leukocyte adhesion is also sensitive to hemodynamics, such that reduced leukocyte adhesion 
levels were observed under high shear conditions and with oscillating flow.  The results show 
that the presence of VTCs can influence blood cell response to an inflamed endothelium in blood 
flow, which may potentially provide therapeutic benefits for inflammatory diseases whose 
pathogenesis is enhanced by leukocyte recruitment.  
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CHAPTER 6  
 
INFLUENCE OF VTCs ON PLATELET ADHESION IN BLOOD FLOW 
 
 
6.1.  Introduction 
Platelets in flow play a critical role in limiting blood loss after vascular injury through the 
adhesion and formation of a platelet plug at the injury site.[1-3]  In healthy tissue, the blood 
vessel endothelium limits platelet interactions by releasing soluble factors, such as nitric oxide 
and prostacyclin, which keep circulating platelets in a quiescent state.[4]  However, there are 
cases related to vessel inflammation in which the adhesion of activated platelets to the 
endothelium enhances or initiates disease pathogenesis.  For example, in arterial and venous 
thrombosis, activated platelets initiate blood coagulation onto the vessel wall after which the 
thrombus (aggregated platelets cross-linked with a fibrin network) may rupture due to shear 
stress and initiate a cardiac event such as a stroke or myocardial infarction (heart attack).  Thus, 
in order for VTCs to be biocompatible with blood and implemented for treating diseases such as 
venous thrombosis, they must not alter platelet function where necessary (i.e. vascular injury) or 
induce platelet activation and aggregation at inflammatory sites.  
One factor in determining platelet compatibility is investigating the upregulation of P-
selectin.[5, 6]  P-selectin expressed on activated platelets, or released on platelet microparticles 
(PMPs), plays a significant role in forming platelet-platelet and platelet-leukocyte aggregates.[7] 
Dynamics with activated platelets are of particular interest regarding sLe
a
-targeted VTCs due to 
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sLe
a
 also being a ligand for P-selectin.[8, 9]  It is unclear if locally activated platelets interact 
with sLe
a
-targeted spheres in circulation and what effect targeted spheres have on platelet 
adhesion to an inflamed endothelium, i.e. does the presence of sLe
a
-targeted spheres induce and 
enhance platelet adhesion to the endothelium through P-selectin-sLe
a 
bridging.   
Utilizing particle-platelet dynamics in flow has also been proposed as viable strategy for 
enhancing platelet adhesion and aggregation in traumatic injuries with rapid blood loss, 
specifically for patients with thrombocytopenia (< 1x10
8
 platelets/mL blood).[10]  Synthetic 
platelets are VTCs designed to mimic platelet function; that is, (1) synthetic platelets target and 
adhere to exposed collagen and vWF during vessel injury under a range of shear stresses, and (2) 
co-localized with platelets and aide in forming a stable platelet plug.[11-13]  Nano-liposomes 
have commonly been explored as synthetic platelet options due to their low toxicity in blood and 
ability to mimic platelet function when decorated with peptides which interact with platelet 
receptors such as collagen, vWF, and fibrinogen.  However, previous work has demonstrated that 
nanospheres (200 nm – 500 nm) do not effectively marginate in human blood flow.[14, 15]  
Despite the fact that 2 – 3 µm spheres are approximately the same size of human platelets and 
efficiently marginate and adhere to the vessel wall in blood flow, this size range has not been 
extensively explored for mimicking and enhancing platelet function. 
 In this study I examine the effect of particle-platelet dynamics on platelet adhesion in 
blood containing physiological and low platelet concentrations (1x10
8
 platelets/mL or 5x10
7 
platelets/mL, respectfully).  First, the influence of 2 µm sLe
a
-targeted spheres on platelet 
adhesion to an inflamed endothelium is assessed to determine if the presence of targeted 
microspheres activate platelets in reconstituted blood flow.  Second, the adhesion of activated 
platelets was examined to determine if targeted spheres present in flow enhances the adhesion of 
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activated platelets to an inflamed endothelium.  Finally, 2 µm spheres targeted with two dual-
peptide systems, (1) collagen binding peptide (PEG-CBP)/PEG-cRGD or (2) and vWF binding 
peptide (PEG-VBP)/PEG-cRGD, were explored as possible platelet mimicking VTCs to enhance 
platelet adhesion to collagen or vWF under laminar blood flow. 
   
6.2  Results 
 The experimental set up used in this chapter is described in detail in Chapter 2. 
 
6.2.1.  Unactivated Platelet Adhesion to an Activated Endothelial Monolayer in the 
Presence of sLe
a
-Targeted Microspheres. 
In order to investigate if inflammation targeting VTCs influence platelet adhesion in 
blood flow, reconstituted blood (plasma, RBCs, leukocytes) containing unactivated platelets 
(1x10
8
 platelets/mL) and 2 µm sLe
a
-targeted spheres (5x10
5
 particles/mL) was perfused over an 
activated endothelium and the adhesion of platelets and targeted spheres was examined at 200 s
-
1
, 500 s
-1
, and 1,000 s
-1 
WSR (Fig. 6.1).  There was no significant effect on platelet adhesion 
between particle-free blood and blood containing targeted spheres at all WSRs examined.  The 
particle adhesion density significantly increased with increasing WSR.  Platelets adhesion, 
however, decreased by 2-fold and 4-fold, relative to the platelet adhesion with 200 s
-1
 WSR, 
when increasing the WSR from 500 s
-1
 to 1,000 s
-1
, respectfully.  PEGylated 2 µm spheres (2.3 
kDa PEG, 32,270 PEG chains/µm
2
, intermediate-brush conformation) were also examined to 
determine if the addition of a PEG corona would induce platelet adhesion through activation.  
PEGylated spheres were shown to have no significant effect on platelet adhesion at 500 s
-1
 WSR, 
and the platelet and particle adhesion levels were similar to that observed with non-PEGylated 
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spheres at the same WSR (Fig. 6.1, 6.2).    
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Figure 6.1.  Adhesion of unactivated platelets (1x10
8
/mL) and 2 µm sLe
a
-targeted spheres 
(1,000 sLe
a
 sites/µm
2
, 5x10
5
/mL) to an activated endothelium in reconstituted blood flow at 
(A) 200 s
-1
 WSR
 
for 5 minutes, (B) 500 s
-1
 WSR
 
for  3 minutes, and (C) 1,000 s
-1
 WSR
 
for 3 
minutes. 
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Figure 6.2.  Adhesion of unactivated platelets (1x10
8
 platelets/mL) and 2 µm PEGylated (2.3 
kDa PEG, 32,270 PEG chains/µm
2
) sLe
a
-targeted spheres (1,000 sLe
a
 sites/µm
2
) to an 
activated endothelium in reconstituted blood flow at  500 s
-1
 WSR for 3 minutes. 
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6.2.2.  Activated Platelet Adhesion to an Activated Endothelial Monolayer in the Presence 
of sLe
a
-Targeted Microspheres. 
The adhesion of activated platelets to an activated endothelium in blood flow was 
examined with the presence of non-targeted and sLe
a
-targeted 2 µm spheres in blood at a 
concentration of 5x10
5
 particles/mL.  Similar to what was observed with non-activated platelets, 
2 µm spheres did not significantly affect platelet adhesion to an activated endothelium (Fig. 6.3).  
The presence of targeted spheres on activated platelet adhesion in blood with a 
thrombocytopenic platelet concentration (5x10
7
 platelets/mL) was also examined to determine if 
the lack of a significant effect on activated platelet adhesion was a result of the ~3-orders of 
magnitude difference in blood concentration between platelets and microspheres (1x10
8
 
platelets/mL and 5x10
5
 particles/mL, respectfully).  With 5x10
5
 particles/mL blood 
concentration, 2 µm non-targeted spheres decreased platelet adhesion by 2-fold; however, the 
presence of sLe
a
-targeted spheres at the same blood concentration had no significant effect on 
platelet adhesion to the endothelium (Fig. 6.4.A).  There was also no significant effect on 
activated platelet adhesion with targeted spheres in 1x10
6
 particles/mL blood concentration (Fig. 
6.4.B), even though the particle adhesion was ~2.3-fold higher than the adhesion of targeted 
spheres with 5x10
5
 particles/mL blood concentration (Fig. 6.4.A).  Non-targeted spheres at 1x10
6
 
particles/mL in blood did not significantly affect activated platelet adhesion at the WSR explored 
(1,000 s
-1
).  The effect sLe
a
 ligand density on activated platelet adhesion was examined using 
microspheres with 900 and 2,800 sLe
a
 sites/µm
2
 to investigate if increased sLe
a
 density on target 
microspheres would promote sLe
a
-mediated capture of platelets to the endothelium.  There was 
no significant effect on platelet adhesion from the presence of targeted spheres with either ligand 
densities (Fig. 6.5).   
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Figure 6.3.  Adhesion of α-thrombin (1 nM) activated platelets (1x108/mL) with non-
targeted or sLe
a
-targeted 2 µm spheres (5x10
5
/mL, 1,000 sLe
a
 sites/µm
2
) at 1,000 s
-1
 WSR. 
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Figure 6.4.  Adhesion of ADP (adenosine diphosphate, 1 µM) activated platelets (5x10
7
/mL) 
with 2 µm sLe
a
-targeted spheres with blood concentrations of (A) 5x10
5 
particles/mL and (B) 
1x10
6
 particles/mL (1,000 sLe
a
 sites/µm
2
) in reconstituted blood flow with 1,000 s
-1
 WSR. 
(A) * indicated significant difference compared to particle-free blood.  
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Figure 6.5.  Influence of sLe
a
 density on ADP (1 µM) activated platelet adhesion (5x10
7
/mL) 
at 1,000 s
-1
 WSR.  
 
 
 
 
 
  
137 
6.2.3.  Tri-Peptide Targeted Microspheres for Enhancing Platelet Adhesion to an Injury 
Model 
To investigate whether platelet-mimicking microspheres promote platelet adhesion and 
aggregation to collagen or vWF surfaces in blood containing low platelet concentration (5x10
7
 
platelets/mL), 2 µm avidin-coated polystyrene microspheres were incubated with biotin-
PEG3.4kDa-CBP or biotin-PEG3.4kDa-VBP along with PEG3.4kDa-cRGD in a 50-50 ratio (50% CBP 
or VBP and 50% cRGD, 5 µg/mL working concentration for each peptide). The particle and 
platelet adhesion was assessed at 200 s
-1
 or 1,000 s
-1
 to collagen or vWF coated glass coverslips, 
respectfully ( peptides were procured by Christa Modery-Pawlowski and Dr. Anirban Sen Gupta 
at Case Western Reserve University).  For all blood conditions, platelet adhesion was 
significantly greater to collagen and vWF surfaces compared to BSA surfaces, indicating that the 
platelet adhesion was mediate through collagen or vWF and not through non-specific interactions 
with BSA or exposed glass (Fig. 6.6).  The addition of non-targeted microspheres slightly 
increased platelet adhesion to collagen under 200 s
-1
 of laminar blood flow relative to particle-
free blood; however, this increase was not significantly different with a 99% confidence level 
(p=0.0469).  The presence of CBP/cRGD-coated microspheres did not affect platelet adhesion to 
collagen under the same shear conditions, relative to particle-free blood (Fig. 6.6.A).  The 
platelet adhesion level to collagen with the presence of peptide-targeted microspheres was not 
significantly different than the platelet level observed with non-targeted microspheres at the 
same particle concentration in blood (p = 0.1255, Fig. 6.6.A).   Both non-targeted and 
VBP/cRGD-coated microspheres did not influence platelet adhesion to vWF under 1,000 s
-1
 of 
laminar blood flow (Fig. 6.6.B).  No particle adhesion was observed with either CBP/cRGD or 
VBP/cRGD targeted 2 µm spheres.   In order to elucidate if the lack of particle adhesion, and 
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thus influence on platelet adhesion, was due to low peptide densities on the microspheres, biotin-
PEG-CBP-FITC was incubated with avidin-coated microspheres at a same peptide concentration 
used to prepare the targeted particles used in Fig. 6.6.A (5 µg/mL).  Flow cytometry was used to 
obtain a fluorescent histogram to indicate if the fluorescent peptide was grafted to the 
microsphere’s surface.  There was a minimal shift in fluorescent histogram, compared to non-
fluorescent peptide-targeted spheres, indicating that there was a minimal peptide density grafted 
onto the microspheres (Fig. 6.7).      
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Figure 6.6.  Adhesion of platelets (5x10
7
/mL, 1 µM ADP activated) to (A) collagen (200 s
-1
 
WSR) and (B) von Willebrand binding (1,000 s
-1
) with peptide-targeted microspheres.  * 
indicates significant difference in platelet adhesion compared to BSA coated glass coverslips 
(p<0.01).   
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Figure 6.7.  Fluorescent histogram of 2 µm avidin-coated microspheres incubated with 5 
µg/mL biotin-PEG-CBP-FITC (blue); control histograms of avidin coated microspheres 
without incubation (red) and carboxylated polystyrene microspheres incubated with 100 
µg/mL biotin-PEG-CBP-FITC (purple).  
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6.3.  Discussion 
 Platelet activation, aggregation, and adhesion at injury sites are critical processes in 
minimizing blood loss at sites of vessel injury.  However, platelet adhesion and aggregation at 
inflammatory sites may result in thrombus formation leading to cardiovascular events such as a 
stroke or complete vessel occlusion.  Thus, it is crucial that VTCs designed to therapeutically 
treat inflammation do not induce platelet activation, adhesion, or thrombus formation at the 
targeted vessel wall.  This study shows that 2 µm sLe
a
-targeted polystyrene spheres have no 
significant effect on the adhesion of activated or unactivated platelets to an inflamed 
endothelium.  Unactivated platelets, via the surface protein GP1bα within the GPIb-IX-V 
complex, interact through rolling adhesion with ultra-large vWF (ULVWF) secreted by cytokine-
stimulated endothelium.[2, 16]    However under shear stress, protease ADAMTS-13 in plasma 
rapidly cleaves ULVWF into smaller chains in order to minimize platelet-endothelial interactions 
during inflammation.[17]  Activation induced platelet aggregation, through platelet activating 
factors such as ADP or α-thrombin or exposure to shear rates >10,000 s-1 can strengthen platelet-
vWF interactions and lead to platelet firm adhesion to the endothelium.[18]  The lack of a 
significant difference in platelet adhesion with the presence of targeted microspheres, relative to 
particle-free blood, suggests that inflammation targeting microspheres: (1) do not interfere with 
the enzymatic mechanism in place to minimize platelet-endothelial interactions in blood flow, 
(2) do not promote firm adhesion to the endothelium through platelet activation and subsequent 
aggregation. Interestingly, non-targeted carboxylated and amidine polystyrene spheres (< 100 
nm) have been shown to activated platelets and upregulate P-selectin expression of platelets in 
plasma.[19]  While only 2 µm spheres were explored in this work, it is possible that polystyrene 
targeted spheres < 100 nm may significantly activate platelets in blood flow; however, it is not 
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anticipated that this would correlate to an increase in platelet adhesion to the endothelium in 
blood flow due to the lack of evidence suggesting that targeted particles interfere with the 
enzymatic cleavage of endothelial released vWF.  
Platelet activation induced by exposure to activating agents such as ADP or α-thrombin, 
results in an increase in platelet P-selectin expression which may induce platelet-particle 
aggregates through P-selectin and sLe
a
 on targeted VTCs.[20, 21]  Thus, I examined if sLe
a
-
targeted spheres affect activated platelet adhesion to an endothelium through P-selectin-sLe
a
 
interactions (i.e. increase in platelet adhesion mediated by sLe
a
-targeted spheres present on the 
endothelium).  SLe
a
-targeted microspheres did not affect activated platelet adhesion to the 
endothelium, relative to particle-free blood (Fig. 6.3).  Increasing the particle blood 
concentration (resulting in a higher particle adhesion density) or sLe
a 
ligand density in blood 
containing ADP activated platelets also had no significant impact on platelet adhesion in blood 
flow (Fig. 6.4.B and Fig. 6.5).  Previously, sLe
a
-targeted microbubbles were shown to adhere to 
immobilized activated platelets under flow; however, the capture efficiency significantly 
decreased from 16% to 3.4% when increasing shear stress from 5 dyn/cm
2 
to 40 dyn/cm
2
 (~125 s
-
1
 and 1,000 s
-1
 blood WSR, respectfully).[22]  It is likely that the lack of an increase in platelet 
adhesion through sLe
a
 capturing from endothelial bound microspheres may be a result of the 
high WSR explored (1,000 s
-1
), which is similar to the WSRs present in large arteries susceptible 
to cardiovascular disease.[23]  Overall, the results suggest that sLe
a
-targeted model VTCs do not 
influence platelet adhesion to an activated endothelium in blood flow; however, further 
investigation is required to elucidate if platelet capture via sLe
a
-targeted microspheres would 
occur with greater particle blood concentrations or under venous shear conditions (< 200 s
-1
) 
relevant to vessels which develop venous thrombosis.[23]  
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The potential for particle-platelet dynamics influencing platelet adhesion in blood flow 
was also explored using two dual-peptide systems proposed for mimicking platelet adhesion to 
ECM proteins, collagen or vWF, and promote platelet aggregation at sites of vessel injury.  In 
this work, 2 µm peptide-targeted spheres were shown to have no significant effect on platelet 
adhesion to collagen or vWF surfaces (Fig. 6.6).  Interestingly, no particle adhesion to collagen 
or vWF surfaces was observed under 200 s
-1
 or 1,000 s
-1
 WSR, respectfully.   Nano-liposomes 
decorated with similar CBP and VBP peptides were shown to firmly adhere to collagen and vWF 
surfaces under shear stresses ranging from 5–55 dyn/cm2 (~125–1,364 s-1 blood WSR).[12, 13]  
The lack of an effect on platelet adhesion with 2 µm peptide-targeted spheres may be a result of 
the particles not establishing firm adhesion to collagen or vWF, thus preventing any particle-
platelet aggregation through cRGD on the microspheres from localizing to the protein coated 
surfaces and increasing overall platelet adhesion density.  Fluorescent histograms of avidin-
coated microspheres with biotin-PEG-CBP-FITC show minimal attachment of the CBP-FITC 
peptide to the particle surface (Fig. 6.7).  Thus, it is likely that the steric hindrance from the 
PEGylated peptides used in this work reduced the coupling to avidin-coated microspheres, 
resulting in insufficient ligand densities for establishing firm adhesion under the shear conditions 
explored in this work.  This may also be the case for not observing particle adhesion through 
platelet linkage to collagen or vWF, i.e. the lack of cRGD on microspheres did not induce 
microsphere aggregation with platelets bound to ECM surfaces.  Overall, sLe
a
-targeted 
microspheres did not induce platelet adhesion to an activated endothelium in blood and ECM 
peptide-targeted spheres did not promote or interfere with platelet adhesion to collagen and vWF. 
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CHAPTER 7  
  
CONCLUSIONS AND FUTURE WORK 
 
 
7.1.  Conclusions and Significant Contributions 
Tissue-specific drug delivery is a strategy for improving therapeutic intervention in many 
serious diseases through minimizing therapeutic exposure to healthy tissue and reducing 
systemic side effects.  Inflammation of the vessel wall is a strong candidate for tissue-specific 
therapy due to the prevalence of the vasculature throughout the body, minimally invasive access 
through injections, and the contribution of inflammation to the pathogenesis of several serious 
diseases including atherosclerosis, sepsis, and various cancers.  The complex nature of blood and 
unique roles that each component (RBCs, leukocytes, platelets, and plasma) has on VTC 
margination and adhesion provide challenges when optimizing VTC performance.  While 
simplified blood models, such as RBCs-only in buffer or plasma, offer insight into the 
biophysical dynamics of particle margination and adhesion to the vessel wall, it is important to 
remember that whole blood is the end-all working fluid for particle transport throughout the 
vasculature.  In this work, I show that VTC dynamics with plasma and blood cells (leukocytes 
and platelets) have significant implications on not only VTC design, but also blood cell 
homeostasis during inflammation.  Specifically, the application of PEGylation to combat plasma 
protein adsorption, VTC design characteristics (size, shape, targeting system, concentration in
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blood), and endothelial surface coverage significantly impact particle adhesion and leukocyte 
recruitment to the vascular wall in blood flow. 
 
7.1.1. PEGylation and VTC Design and Applications 
I demonstrated that the implementation of a PEG corona, with the intent of minimizing 
plasma adsorption, significantly impacts VTC adhesion in physiological blood flow conditions. 
The adhesion characteristics of the targeting system providing tissue specificity ultimately 
determine how PEG affects targeting and which PEG corona parameters, molecular weight 
and/or conformation, are important for VTC performance and application.  For a less efficient 
targeting system, such as the aICAM-1/ICAM-1 system used in this work, both conformation 
and PEG molecular weight affect VTC design.  For applications in high shear, such as the 
conditions in medium to large arteries susceptible to cardiovascular diseases, large PEG spacers 
(5.5 kDa and 10 kDa) oriented in the extended conformation are best suited for effective 
adhesion to the vessel wall.  However, PEG’s ability to maintain the adhesion efficiency of a less 
favorable targeting system has significant implications on tissue specificity, as high levels of 
VTC adhesion with low ligand densities may result in VTCs targeting diseased and healthy 
tissue if the targeted receptor is expressed in both states (as in the case of ICAM-1).  Conversely, 
the enhanced adhesiveness may provide VTCs access to additional targeting systems such as 
monovalent ligands, peptides, and other receptor-ligand systems with adhesive kinetics similar to 
aICAM-1/ICAM-1.  Ultimately, PEGylated VTCs may work best in conjunction with a less 
efficient and highly disease-specific targeting system, or an efficient targeting system. 
For efficient targeting systems like sLe
a
/E-selectin, where the ligand kinetics allow for 
adhesion at WSRs >500 s
-1
 in blood, PEG conformation (i.e. grafted PEG density) is the 
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important factor for maintaining adhesion in blood flow (as the mushroom conformation reduced 
adhesion under WSRs >500 s
-1
).  Moreover, the steric hindrance provided by a unimodal PEG 
corona (single PEG length) in the extended brush orientation, which is the conformation 
suggested to reduce plasma protein adsorption and minimizing particle clearance from blood, 
does not reduce the adhesiveness of targeted micro- and nano-spheres under physiological blood 
flow conditions.  However, an extended brush conformation or high molecular PEG spacer may 
provide a limitation to cellular internalization.  As a result, VTCs for intracellular drug delivery 
may be limited to highly efficient (and disease-specific) targeting systems with low molecular 
weight PEG spacers (≤ 2.3 kDa) in the extended brush conformation.  On the other hand, 
imaging or diagnostic applications would benefit more from high levels of endothelial surface 
coverage (i.e. particle adhesion density) and the limitation on internalization from larger PEG 
spacers would be less important.  Thus for cardiovascular diagnostics or imaging, a 10 kDa PEG 
spacer may provide the best surface coverage through ensuring adhesion under high shear 
conditions, particularly if one were to image highly late-stage develop atherosclerosis where 
shear rates can be >1,000 s
-1
.  
Regardless of the application, the VTC itself must be composed of a biocompatible 
material.  PLGA is the most common biomaterial for drug delivery.  The negative human plasma 
effect on the adhesion of PLGA micro- and nano-spheres provides a significant challenge for the 
application of PLGA VTCs.   While it is commonly thought that PEGylation may neutralize this 
effect through minimizing plasma protein adsorption, the influence of PEG on the adhesion of 
PLGA spheres in human blood has not been thoroughly examined.  I show that the addition of a 
5.5 kDa or 10 kDa PEG spacer corresponding to in an intermediate-brush conformation (~16,000 
and 3,200 PEG chains/µm
2
, respectfully) was unable to restore the adhesion of sLe
a
-targeted 
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PLGA spheres in human blood, relative to plasma-free systems.  However, increasing the PEG 
density of a 5.5 kDa spacer to ~35,000 PEG chains/µm
2
 did restore the adhesiveness of 
polystyrene spheres in pig plasma in which a similar plasma effect as PLGA spheres in human 
blood has been identified.  Based on this result, I hypothesize that a PEG density of at least 
35,000 PEG chains/µm
2
 is required to restore the adhesiveness of PLGA spheres in human 
blood.  While this high of a PEG density (and dense brush conformation) will allow researchers 
to optimize VTC targeting or tissue specificity in a pig in vivo system (which is a good in vivo 
system for cardiovascular disease), it may significantly hinder cellular internalization for drug 
delivery applications.  Similarly, increasing the PEG density onto PLGA VTCs still remains a 
challenge due to the limited functional groups available for PEGylation.  The inability to achieve 
a dense brush conformation or restore the adhesion of PLGA VTCs with low PEG densities may 
restrict PLGA VTCs to therapeutic formulations where a low therapeutic dose is highly effective, 
such as gene delivery.  Overall, PEGylation is more than a strategy for minimizing plasma 
adsorption.  The significant influence of the PEG corona parameters (PEG density and molecular 
weight), targeting system, hemodynamics, and plasma adsorption all contribute to the eventual 
applicability of PEGylated VTCs.  Figure 7.1 shows my general recommendations for designing 
PEGylated VTCs to target inflammation associated with cardiovascular disease based on the 
results of this work. 
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       Figure 7.1.  Schematic of recommendations for designing and applying  
      PEGylated VTCs for targeting inflammation associated with cardiovascular     
      disease in blood. 
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7.1.2.  VTCs and Blood Cell Recruitment to Targeted Tissue 
 While drug delivery formulations are often designed to specifically target or affect one 
particular tissue/cell type, it is important to remember that diseased tissue is a multicellular 
environment which may induce a natural and healthy response from blood cells.  The disruption 
of healthy functioning cells at the diseased site may have significant repercussions on the 
effectiveness and applicability of targeted drug delivery systems.  For example, VTCs increasing 
platelet interaction with the vessel wall and initiating a thrombus at the target site would 
inherently be counterproductive.  In this work, I show that the presence of VTCs do not initiate 
platelet aggregation at the target site.  More importantly, the presence of VTCs in blood or at the 
vessel wall does not disrupt the homeostatic cleavage of endothelial released vWF by plasma 
enzymes, which is a mechanism used to minimize platelet interaction with inflammatory tissue.  
This alleviates potential concerns of VTCs inducing blood coagulation at the vascular wall. 
On the other hand, reducing the accumulation of blood cells at the target site that 
accelerate disease pathogenesis could provide a therapeutic benefit.  In Chapters 5, I show that 
particles targeted with either sLe
a
 or aICAM-1 significantly reduce leukocyte recruitment to the 
same targeted endothelium.  The reduction in leukocyte adhesion was determined to be 
dependent on carrier size, particle adhesion density, and hemodynamics.  In fact, 5 µm and 3 µm 
present at the highest concentration explored (1x10
7
 particles/mL in blood) reduced leukocyte 
adhesion by nearly 100%.  Most interestingly, nanospheres (500 nm) were also shown to 
significantly reduce leukocyte recruitment by nearly 40%.  A potential benefit of this 
phenomenon may be in the application of VTCs as a passive anti-inflammatory therapy.  Current 
anti-inflammation (anti-leukocyte adhesion) therapies include functional blocking antibodies 
directed towards key CAMs (i.e. ICAM-1 or E-selectin) and therapeutics geared towards 
152 
reducing CAMs expression.  However, to date, these strategies have not shown long-term 
benefits due to short half-lives of the antibodies/therapeutics.  A major concern with these 
systemic molecular-based anti-adhesion therapies is balancing the therapeutic blocking of 
leukocyte recruitment to chronically inflamed tissue, associated with diseases, without affecting 
recruitment to inflammatory sites where needed (i.e. local infection).  Tissue-specific drug 
delivery may potentially alleviate this effect by delivering anti-inflammatory therapeutics 
directly to diseased tissue.  Additionally, VTCs reducing leukocyte accumulation at 
inflammatory tissue, via physical/competitive interactions with leukocytes at the vessel wall, 
may significantly enhance the therapeutic treatment of inflammatory diseases associated with 
leukocyte recruitment such as atherosclerosis, sepsis, or reperfusion injury.  In this case, VTCs 
themselves may be developed as therapy, or work in conjunction with an anti-inflammatory 
therapeutic, for effective and local treatment of inflammatory diseases.  Examining the effect of 
targeted drug carriers in a multicellular environment not only examines the effect of drug carriers 
on healthy cell function, but may provide new information or identify new avenues for 
enhancing disease treatment.       
 
7.2.  Future Work 
 The contributions of this work have provided valuable information demonstrating how 
the dynamics between blood and VTCs in circulation affect VTC performance and potential 
applications.  However, there are still specific areas in which VTC-blood dynamics can be 
developed for optimizing VTC function.  For example, studying tissue-site retention of 
PEGylated spheres, relative to non-PEGylated spheres, will add an additional specification to 
PEGylated VTC design.  While there has been significant work investigating how PEGylation 
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influences the biodistribution (organ accumulation) of model VTCs, there has been little work 
examining target site retention.  This could have significant applications in real-time imaging and 
tracking treatment progress.  Additionally, highly developed atherosclerotic tissue can reach wall 
shear rates of up to 10,000 s
-1
.  Examining the influence of PEGylation on VTC adhesion at 
shear rates greater than the 1,000 s
-1
 used in this work, would determine whether the sizes of the 
PEG spacer used in this work (2.3 kDa, 5.5 kDa, and 10 kDa) are sufficient for targeting late-
stage atherosclerosis or would be limited tissue with low levels of plaque. 
 The high PEG density recommended for improving PLGA adhesion in human blood 
(~35,000 PEG chains/µm
2
) provides a serious challenge for PLGA drug delivery systems.  Due 
to the limited functional groups available with PLGA, I recommend developing a one-step 
fabrication procedure for simultaneous particle fabrication and PEGylation using PLGA-PEG-
copolymers or PLGA/PLGA-PEG-copolymer blends and an emulsion-solvent-evaporation 
technique.  This would eliminate the need for a post-fabrication PEGylation step, such as the 
carboxyl-amine chemistry used in this work, of which the amount of PEG grafted to the particles 
is is limited by the density of functional groups present on the surface of PLGA particles.  It will 
also be important to determine the uptake efficiency of the PEGylated spheres by the targeted 
tissue, i.e. an activated endothelium in the case for inflammation, as this would determine 
whether restoring PLGA adhesion in human blood using a high PEG density would also limit the 
potential implementation of PEGylated PLGA spheres for intracellular delivery.   
 PEGylation should also be investigated as a VTC modification for improving the 
effectiveness of nanospheres in reducing leukocyte recruitment to inflammatory tissue.  I 
hypothesize that nanospheres reduce leukocyte recruitment to inflammatory tissue through a 
combined effect of occupying adhesion molecules at the target site and interacting with 
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leukocytes away from the vessel wall.  Specifically, sLe
a
-targeted nanospheres are more efficient 
than aICAM-1 targeted nanospheres due to the sLe
a
 spheres potentially interacting with L-
selectin on leukocytes.  The stability of these potential nanosphere-leukocyte aggregates is 
unknown, as the interaction of sLe
a
 with L-selectin has much faster adhesive kinetics (on-/off- 
rate), relative to the kinetics of sLe
a
 and E-selectin.  The improved adhesiveness with 
PEGylation may stabilize leukocyte-nanosphere aggregates or promote the formation of more 
aggregates, thus improving the effectiveness of nanospheres in reducing leukocyte accumulation.  
This would have a significant implication on the applicability of VTCs as an anti-inflammatory 
therapy as the maximum reduction in leukocyte recruitment was observed with 5 µm and 3 µm 
spheres, which are susceptible to capillary entrapment due to their size.    
Another possible way to improve the effectiveness of small VTCs (2 µm or 500 nm) 
would be to examine the effect of material density on leukocyte reduction.  VTCs < 5 µm 
primarily influence leukocyte recruitment through endothelial surface coverage (particle 
adhesion density) and not through physical collisions with endothelial interacting leukocytes.  
Increasing the density of the particle provide a collision component, in addition to the effect from 
endothelial surface coverage, and increase the effectiveness of small VTCs.  As an example, 
based on a simple estimation of momentum (particle volume x material density x velocity), if the 
particle velocity is assumed to be similar to that recorded in Fig. 2.5 (~40 mm/s), a 2 µm sphere 
would require a particle density of approximately 15 g/cm
3
 (which is similar to that of gold, ~19 
g/cm
3
), to achieve a similar momentum as 5 µm polystyrene spheres and possibly provide a 
collision effect for 2 µm spheres in reducing leukocyte adhesion.    
Overall, it is important to examine whether VTCs provide an enhanced therapeutic 
benefit, relative to current antibodies used for anti-adhesion therapies, before devoting 
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significant resources to improving nanoparticle effectiveness on reducing leukocyte adhesion.  
This could potentially be examined by implementing endothelial permeability studies in 
combination with the flow assays used in this work, as an increase in endothelial permeability is 
one symptom of non-regulated leukocyte accumulation associated with diseases like ischemia-
reperfusion injury.  However, investigating the therapeutic effect of VTCs reducing platelets 
aggregation to inflammatory tissue in diseases such as deep vein thrombosis is more challenging.  
In vivo animal models are commonly implemented for studying deep vein thrombosis; however, 
developing in vitro assays using human platelets may provide better analysis before eventual pre-
clinical trials due to differences in animal blood functionality relative to humans.  My 
recommendation for developing an in vitro thrombosis assay is to implement a cone-and-plate 
viscometer in a similar fashion used to culture bacterial biofilms in vitro.  This would allow for 
determining if the presence of VTCs influences the development of thrombus formation or if 
VTCs destabilize thrombi, which could potentially put patients at high risk for a cardiac event.      
In summary, while simplified blood models are often used to gain a better understanding 
as to the biophysics of VTC adhesion, VTC performance in blood with all its components 
present will determine VTC design and applicability.  A simple modification such as PEGylation 
for minimizing plasma adsorption has a significant effect on VTC adhesion in blood.  The high 
PEG density required to restore adhesion of a plasma-sensitive drug delivery system in blood 
may in turn reduce its uptake efficiency and limit its potential for intracellular drug delivery.  
Conversely, the ability of 500 nm spheres to reduce leukocyte accumulation at inflammatory 
tissue in blood may be a new therapeutic avenue for vascular targeting.  Overall, targeted drug 
delivery systems must be examined in multicomponent systems similar to that of the targeted 
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environment, as the success of tissue-specific drug delivery will ultimately be determined by its 
ability to effectively treat diseases without affecting healthy tissue function.   
 
 
 
 
